<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">98386</article-id><article-id pub-id-type="doi">10.7554/eLife.98386</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.98386.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Developmental Biology</subject></subj-group></article-categories><title-group><article-title>VGLL2 and TEAD1 fusion proteins identified in human sarcoma drive YAP/TAZ-independent tumorigenesis by engaging EP300</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Guo</surname><given-names>Susu</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7481-6884</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Hu</surname><given-names>Xiaodi</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Cotton</surname><given-names>Jennifer L</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0106-1801</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Ma</surname><given-names>Lifang</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Qi</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Cui</surname><given-names>Jiangtao</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Yongjie</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Thakare</surname><given-names>Ritesh P</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Tao</surname><given-names>Zhipeng</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Ip</surname><given-names>Y Tony</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4370-7906</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Xu</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Wang</surname><given-names>Jiayi</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1688-2864</contrib-id><email>jiayi.wang@sjtu.edu.cn</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Mao</surname><given-names>Junhao</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1980-1177</contrib-id><email>Junhao.Mao@umassmed.edu</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0220qvk04</institution-id><institution>Department of Clinical Laboratory, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Shanghai</named-content></addr-line><country>China</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0464eyp60</institution-id><institution>Department of Molecular, Cell and Cancer Biology, University of Massachusetts Chan Medical School</institution></institution-wrap><addr-line><named-content content-type="city">Worcester</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0464eyp60</institution-id><institution>Program in Molecular Medicine, University of Massachusetts Chan Medical School</institution></institution-wrap><addr-line><named-content content-type="city">Worcester</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Cutaneous Biology Research Center, Massachusetts General Hospital, Harvard Medical School</institution></institution-wrap><addr-line><named-content content-type="city">Charlestown</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Shi</surname><given-names>Xiaobing</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00wm07d60</institution-id><institution>Van Andel Institute</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Postovit</surname><given-names>Lynne-Marie</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02y72wh86</institution-id><institution>Queens University</institution></institution-wrap><country>Canada</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>08</day><month>05</month><year>2025</year></pub-date><volume>13</volume><elocation-id>RP98386</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2024-05-01"><day>01</day><month>05</month><year>2024</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2024-05-03"><day>03</day><month>05</month><year>2024</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.05.01.592016"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-07-01"><day>01</day><month>07</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.98386.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-04-15"><day>15</day><month>04</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.98386.2"/></event></pub-history><permissions><copyright-statement>© 2024, Guo, Hu et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Guo, Hu et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-98386-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-98386-figures-v1.pdf"/><abstract><p>Studies on Hippo pathway regulation of tumorigenesis largely center on YAP and TAZ, the transcriptional co-regulators of TEADs. Here, we present an oncogenic mechanism involving VGLL and TEAD fusions that is Hippo pathway-related but YAP/TAZ-independent. We characterize two recurrent fusions, <italic>VGLL2-NCOA2</italic> and <italic>TEAD1-NCOA2</italic>, recently identified in human spindle cell rhabdomyosarcoma. We demonstrate that in contrast to VGLL2 and TEAD1 the fusion proteins are potent activators of TEAD-dependent transcription, and the function of these fusion proteins does not require YAP/TAZ. Furthermore, we identify that VGLL2 and TEAD1 fusions engage specific epigenetic regulation by recruiting histone acetyltransferase EP300 to control TEAD-mediated transcriptional and epigenetic landscapes. We show that small-molecule EP300 inhibition can suppress fusion protein-induced oncogenic transformation both in vitro and in vivo in mouse models. Overall, our study reveals a molecular basis for VGLL involvement in cancer and provides a framework for targeting tumors carrying <italic>VGLL</italic>, <italic>TEAD</italic>, or <italic>NCOA</italic> translocations.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>VGLL2</kwd><kwd>TEAD</kwd><kwd>HIPPO</kwd><kwd>YAP</kwd><kwd>NCOA2</kwd><kwd>EP300</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01DK127207</award-id><principal-award-recipient><name><surname>Mao</surname><given-names>Junhao</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01DK127180</award-id><principal-award-recipient><name><surname>Mao</surname><given-names>Junhao</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01CA238270</award-id><principal-award-recipient><name><surname>Wu</surname><given-names>Xu</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>82173015</award-id><principal-award-recipient><name><surname>Wang</surname><given-names>Jiayi</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Characterization of recurrent fusion proteins in rhabdomyosarcoma identified a Hippo pathway-independent mechanism involving VGLL2 and TEAD1 driving oncogenic transformation.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Hippo signaling, originally identified in <italic>Drosophila</italic> as an organ size control pathway, has emerged as a critical developmental pathway whose dysregulation contributes to the development and progression of a variety of human diseases, including cancer (<xref ref-type="bibr" rid="bib66">Zheng and Pan, 2019</xref>; <xref ref-type="bibr" rid="bib34">Ma et al., 2019</xref>; <xref ref-type="bibr" rid="bib9">Calses et al., 2019</xref>; <xref ref-type="bibr" rid="bib28">Kulkarni et al., 2020</xref>; <xref ref-type="bibr" rid="bib38">Piccolo et al., 2023</xref>). In the mammalian Hippo pathway, activation of the core kinase cascade, which comprises the macrophage stimulating 1/2 (MST1/2) and large tumor suppressor kinase 1/2 (LATS1/2) kinases, leads to phosphorylation, cytosolic retention, and degradation of the key transcriptional coactivators, YAP and TAZ. Upon Hippo pathway inactivation, YAP and TAZ translocate into the nucleus and interact with the TEAD family of transcription factors, thereby inducing downstream gene transcription (<xref ref-type="bibr" rid="bib66">Zheng and Pan, 2019</xref>; <xref ref-type="bibr" rid="bib34">Ma et al., 2019</xref>; <xref ref-type="bibr" rid="bib54">Totaro et al., 2018</xref>). Although the Hippo pathway has been implicated in human cancers, mutations or deletions of the pathway components, such as the MST1/2 or LATS1/2 kinases, are rarely detected in cancers. The focus on Hippo involvement in tumorigenesis has been on the transcriptional co-activators, YAP and TAZ, whose upregulation or nuclear accumulation has been reported in various cancer types (<xref ref-type="bibr" rid="bib38">Piccolo et al., 2023</xref>; <xref ref-type="bibr" rid="bib52">Thompson, 2020</xref>; <xref ref-type="bibr" rid="bib18">Franklin et al., 2023</xref>). In addition, recent studies identified YAP and TAZ fusion proteins as oncogenic drivers in several tumors, including epithelioid hemangioendothelioma, supratentorial ependymoma, porocarcinoma, epithelioid fibrosarcoma, and NF2-wildtype meningioma (<xref ref-type="bibr" rid="bib15">Driskill et al., 2021</xref>; <xref ref-type="bibr" rid="bib42">Seavey et al., 2021</xref>; <xref ref-type="bibr" rid="bib35">Merritt et al., 2021</xref>; <xref ref-type="bibr" rid="bib46">Szulzewsky et al., 2021</xref>; <xref ref-type="bibr" rid="bib47">Szulzewsky et al., 2022</xref>; <xref ref-type="bibr" rid="bib19">Garcia et al., 2022</xref>), further highlighting the critical role of YAP/TAZ in tumorigenesis.</p><p>The mammalian VGLL family proteins (VGLL1-4) are expressed in various tissues, and it is thought that VGLL proteins carry out their cellular function via interaction with TEADs (<xref ref-type="bibr" rid="bib17">Faucheux et al., 2010</xref>; <xref ref-type="bibr" rid="bib39">Pobbati et al., 2012</xref>; <xref ref-type="bibr" rid="bib43">Simon et al., 2016</xref>; <xref ref-type="bibr" rid="bib59">Yamaguchi, 2020</xref>). However, in comparison to YAP and TAZ, little is known about their functional regulation. Among the VGLL proteins, VGLL4 and its <italic>Drosophila</italic> homolog Tgi have been demonstrated as transcriptional repressors by competing with YAP/TAZ binding to TEADs through two TONDU (TDU) domains (<xref ref-type="bibr" rid="bib27">Koontz et al., 2013</xref>; <xref ref-type="bibr" rid="bib8">Cai et al., 2022</xref>; <xref ref-type="bibr" rid="bib64">Zhang et al., 2014</xref>; <xref ref-type="bibr" rid="bib31">Li et al., 2023</xref>). In contrast, the precise function of VGLL1-3 in both normal and tumor cells and how they influence Hippo/YAP signaling and affect TEAD transcriptional output remain poorly understood.</p><p>Several recent studies have identified the recurrent rearrangement of the <italic>VGLL2</italic> and <italic>TEAD1</italic> genes in a large subset of spindle cell rhabdomyosarcoma (scRMS), a pediatric form of RMS that is distinct from embryonic RMS (ERMS) (<xref ref-type="bibr" rid="bib1">Alaggio et al., 2016</xref>; <xref ref-type="bibr" rid="bib48">Tan et al., 2020</xref>; <xref ref-type="bibr" rid="bib11">Chen et al., 2020</xref>; <xref ref-type="bibr" rid="bib14">Cyrta et al., 2021</xref>; <xref ref-type="bibr" rid="bib58">Whittle et al., 2022</xref>). In these fusions, <italic>VGLL2</italic> and <italic>TEAD1</italic> participate as 5′ partners in the recurrent translocations, and their 3′ fusion partners often involve the <italic>NCOA2</italic> gene on 8q13.3 (<xref ref-type="bibr" rid="bib1">Alaggio et al., 2016</xref>). Among these fusion proteins, the <italic>VGLL2-NCOA2</italic> fusion has recently been shown to drive tumor formation in zebrafish and allograft models (<xref ref-type="bibr" rid="bib57">Watson et al., 2023</xref>). Here, we explored the molecular mechanism underlying the oncogenic transformation of VGLL2-NCOA2 and TEAD1-NCOA2 fusion proteins. We revealed that, in comparison to VGLL2 and TEAD1, VGLL2-NCOA2 and TEAD1-NCOA2 are robust activators of TEAD-mediated transcription. We demonstrated that VGLL2-NCOA2 and TEAD1-NCOA2-controlled transcriptional activation is YAP/TAZ-independent, and these fusion proteins specifically engage the CREBBP/EP300 epigenetic factors that are critical for their oncogenic activation.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>VGLL2-NCOA2 and TEAD1-NCOA2 induce TEAD-mediated transcriptional activation</title><p>In <italic>VGLL2-NCOA2</italic> and <italic>TEAD1-NCOA2</italic> fusions, <italic>VGLL2</italic> and <italic>TEAD1</italic> are 5′ partners and maintain the key functional domains at the N-terminus. <italic>VGLL2</italic> retains the TDU domain, while <italic>TEAD1</italic> preserves its TEA DNA binding domain (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). The 3′ partners of the fusions are <italic>NCOA2</italic>, which retains its two C-terminal transcriptional activation domains (TAD) (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). The exons and breaking points of the <italic>VGLL2</italic>, <italic>TEAD1,</italic> and <italic>NCOA2</italic> genes involved in generating the <italic>VGLL2-NCOA2</italic> and <italic>TEAD1-NCOA2</italic> gene arrangement are presented in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>. To test the transcriptional activity of the fusion proteins, we utilized an 8<bold>×</bold>GIIC luciferase reporter that contains 8<bold>×</bold>TEAD DNA binding sites (TBS-Luc) (<xref ref-type="bibr" rid="bib16">Dupont et al., 2011</xref>). When ectopically expressed in HEK293T cells, we found that, in comparison to the VGLL2, TEAD1, and NCOA2 proteins, the VGLL2-NCOA2 and TEAD1-NCOA2 fusion proteins could significantly induce the transcriptional activation of the TBS-Luc reporter, and their activity was comparable to the activated forms of YAP and TAZ, YAP<sup>5SA</sup> and TAZ<sup>4SA</sup>, in which the LATS kinase phosphorylation sites are mutated rendering them constitutively active (<xref ref-type="bibr" rid="bib65">Zhao et al., 2010</xref>; <xref ref-type="fig" rid="fig1">Figure 1B and C</xref>). Additionally, we showed that ectopic expression of VGLL2-NCOA2 and TEAD1-NCOA2 in HEK293T cells promotes cell proliferation (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>), mimicking the pro-growth activity of activated YAP and TAZ. Furthermore, we demonstrated that the ability of VGLL2-NCOA2 to induce downstream transcription requires both its N-terminal VGLL2 and C-terminal NCOA2 fusion parts, and this effect is dose-dependent and not affected by the 5′ or 3′ protein tags (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C–H</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>VGLL2-NCOA2 and TEAD1-NCOA2 Induce TEAD-mediated transcriptional activation.</title><p>(<bold>A</bold>) Schematic representation of protein structure of VGLL2, TEAD1, NCOA2, VGLL2-NCOA2, and TEAD1-NCOA2. Tondu motif (TDU), TEA DNA binding domain (TEA), YAP binding domain (YBD), basic Helix-Loop-Helix (bHLH), Per-Arnt-Sim domain (PAS), nuclear receptor interaction domain (NID), and transcriptional activation domain (TAD). Arrows point to the break points. (<bold>B</bold>) Immunoblot analysis of YAP<sup>5SA</sup>, VGLL2-NCOA2, TEAD1-NCOA2, TAZ<sup>4SA</sup>, TEAD1, VGLL2, and NCOA2 in HEK293T cells transfected with the expression constructs carrying the HA tag. The figure shows the representative results of three biological replicates. (<bold>C</bold>) YAP<sup>5SA</sup>, VGLL2-NCOA2, TEAD1-NCOA2, TAZ<sup>4SA</sup>, TEAD1, VGLL2, and NCOA2 induce transcriptional activation of TBS (TEAD-binding site)-luciferase reporter (TBS-Luc) in HEK293T cells. Data were expressed as mean ± SD. n=3. ****p&lt;0.0001. (<bold>D</bold>) Heatmap showing expression levels of the core genes including <italic>CCN2</italic>, <italic>CCN1</italic>, <italic>ANKRD1,</italic> and <italic>AMOTL2</italic> significantly regulated in HEK293T cells expressing YAP<sup>5SA</sup>, VGLL2-NCOA2, and TEAD1-NCOA2. N=3. (<bold>E</bold>) mRNA expression levels of <italic>CCN2</italic>, <italic>ANKRD1,</italic> and <italic>CCN1</italic> in HEK293T cells expressing YAP<sup>5SA</sup>, VGLL2-NCOA2, TEAD1-NCOA2, TEAD1, VGLL2, or NCOA2. Data were expressed as mean ± SD. n=3; ****p&lt;0.0001. NS, no significance.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Original western blot membranes corresponding to <xref ref-type="fig" rid="fig1">Figure 1B</xref> indicating the relevant bands.</title><p>The molecular weight markers are indicated.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98386-fig1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1sdata2"><label>Figure 1—source data 2.</label><caption><title>Original western blot membranes corresponding to <xref ref-type="fig" rid="fig1">Figure 1B</xref> indicating the relevant bands.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98386-fig1-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98386-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>VGLL2-NCOA2 regulates TEAD-dependent reporter activity.</title><p>(<bold>A</bold>) Schematic representation of the exons and breaking points of the <italic>VGLL2, TEAD1</italic>, and <italic>NCOA2</italic> genes involved in generating <italic>VGLL2-NCOA2</italic> and <italic>TEAD1-NCOA2</italic> gene arrangement. (<bold>B</bold>) EdU staining showing cell proliferation of HEK293T cells transfected with VGLL2-NCOA2 or TEAD1-NCOA2. Bar chart showing the percentage of EdU-positive cells. Scale bars, 200 μm. Data were expressed as mean ± SD. n=3; **p&lt;0.01. (<bold>C</bold>) Immunoblot analysis of VGLL2-NCOA2, VGLL2-NCOA2<sup>∆VGLL2</sup>, and VGLL2-NCOA2<sup>∆NCOA2</sup> in HEK293T cells transfected with the expression constructs carrying the V5 tag. (<bold>D</bold>) TBS-Luc reporter activity in HEK293T cells expressing VGLL2-NCOA2, VGLL2-NCOA2<sup>∆VGLL2</sup>, and VGLL2-NCOA2<sup>∆NCOA2</sup>. Data were expressed as mean ± SD. n=3. ****p&lt;0.0001. (<bold>E</bold>) Immunoblot analysis of VGLL2-NCOA2-V5 in HEK293T cells transfected with different amount of expression constructs. (<bold>F</bold>) VGLL2-NCOA2 promotes the activation of TBS-Luc reporter in dose-dependent manner. Data were expressed as mean ± SD. n=3. ***p&lt;0.001; ****p&lt;0.0001. (<bold>G–H</bold>) Relative mRNA levels of <italic>CCN2</italic>, <italic>ANKRD1</italic>, and <italic>CCN1</italic> in HEK293T cells expressing VGLL2-NCOA2 (<bold>G</bold>) or TEAD1-NCOA2 (<bold>H</bold>) with HA (5′ end), FLAG (3′ end), or V5 (3′ end) tag. Data were expressed as mean ± SD. n=3; NS, no significance.</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>Original western blot membranes corresponding to <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C and E</xref> indicating the relevant bands.</title><p>The molecular weight markers are indicated.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98386-fig1-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1s1sdata2"><label>Figure 1—figure supplement 1—source data 2.</label><caption><title>Original western blot membranes corresponding to <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C and E</xref> indicating the relevant bands.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98386-fig1-figsupp1-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98386-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Analysis of VGLL2-NCOA2, TEAD1-NCOA2, and YAP<sup>5SA</sup> -induced transcriptomes.</title><p>(<bold>A</bold>) Volcano maps of RNA-seq data sets of HEK293T cells expressing VGLL2-NCOA2, TEAD1-NCOA2, or YAP<sup>5SA</sup>. Red dots represent upregulated mRNAs. Blue dots represent downregulated mRNAs. p&lt;0.05, Log<sub>2</sub>FoldChange &gt;1 or &lt; –1. (<bold>B</bold>) Venn diagram showing the overlaps of differentially regulated genes identified by RNA-seq in HEK293T cells expressing VGLL2-NCOA2, TEAD1-NCOA2, or YAP<sup>5SA</sup>. (<bold>C</bold>) KEGG pathway enrichment analysis of differentially regulated genes identified by RNA-seq in HEK293T cells expressing VGLL2-NCOA2, TEAD1-NCOA2 or YAP<sup>5SA</sup>. ‘Hippo signaling pathway’ is highlighted in red.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98386-fig1-figsupp2-v1.tif"/></fig></fig-group><p>To further characterize the downstream transcription induced by VGLL2-NCOA2 and TEAD1-NCOA2, we performed RNA-seq analysis in HEK293T cells overexpressing VGLL2-NCOA2, TEAD1-NCOA2, or YAP<sup>5SA</sup> (<xref ref-type="fig" rid="fig1">Figure 1D</xref>, <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>, <xref ref-type="supplementary-material" rid="supp1 supp2 supp3">Supplementary files 1–3</xref>). We found that all three could robustly drive transcriptional programs in HEK293T cells, and VGLL2-NCOA2- and TEAD1-NCOA2-induced transcription profiles clustered together and appeared to be distinct from the YAP<sup>5SA</sup>-driven program (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). However, similar to activated YAP, the VGLL2-NCOA2, and TEAD1-NCOA2 fusion proteins also strongly induced the expression of <italic>bona fide</italic> TEAD downstream target genes, such as <italic>CCN2 (CTGF</italic>), <italic>CCN1 (CYR61</italic>), <italic>ANKRD1</italic>, and <italic>AMOTL2</italic> (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). This was further confirmed by RT-qPCR analysis, which showed that the transcriptional levels of <italic>CCN1</italic>, <italic>CCN2</italic>, and <italic>ANKRD1</italic> were significantly elevated in the cells expressing VGLL2-NCOA2, TEAD1-NCOA2, or YAP<sup>5SA</sup> but not in those expressing VGLL2, TEAD1, and NCOA2 (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). Taken together, these data suggest that unlike native VGLL2 and TEAD1, VGLL2-NCOA2 and TEAD1-NCOA2 fusion proteins function as strong activators of TEAD-mediated transcription.</p></sec><sec id="s2-2"><title>VGLL2-NCOA2 and TEAD1-NCOA2-induced transcription does not require YAP and TAZ</title><p>Next, we set out to examine how the VGLL2-NCOA2 and TEAD1-NCOA2 fusion proteins interact with YAP/TAZ and TEAD, the well-characterized transcriptional nexus in the Hippo pathway. We performed co-IP assays in HEK293T cells expressing VGLL2-NCOA2, YAP<sup>5SA</sup>, and TEAD1 and demonstrated that VGLL2-NCOA2 was strongly associated with TEAD1 but not YAP<sup>5SA</sup> (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Furthermore, we showed that VGLL2-NCOA2 could bind to the endogenous TEAD proteins; however, we did not detect a strong interaction between VGLL2-NCOA2 and endogenous YAP and TAZ proteins in HEK293T cells (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). In addition, we compared the ability of TEAD1-NCOA2 and TEAD1 to interact with YAP and TAZ. Not surprisingly, TEAD1 was able to bind YAP/TAZ; however, the interaction between TEAD1-NCOA2 and endogenous YAP/TAZ was not detected (<xref ref-type="fig" rid="fig2">Figure 2C</xref>), which is consistent with the absence of the C-terminal YAP/TAZ binding domain in the TEAD1-NCOA2 fusion. Together, these co-IP assays revealed the lack of association between the VGLL2 and TEAD1 fusion proteins and YAP/TAZ, suggesting that the regulation of transcription by the fusion proteins is likely TEAD-dependent but YAP/TAZ-independent.</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>VGLL2-NCOA2 and TEAD1-NCOA2-induced transcription does not require YAP and TAZ.</title><p>(<bold>A</bold>) Co-IP assays showing VGLL2-NCOA2 binding to TEAD1 but not YAP<sup>5SA</sup>. YAP<sup>5SA</sup>-Flag or TEAD1-Flag was co-expressed with VGLL2-NCOA2-HA in HEK293T cells and immunoprecipitated with an anti-HA antibody. (<bold>B</bold>) VGLL2-NCOA2 binds to endogenous TEAD but not YAP/TAZ. Endogenous YAP/TAZ and TEAD proteins in HEK293T cells were detected by anti-YAP/TAZ and panTEAD antibodies, respectively. (<bold>C</bold>) Co-IP assays showing endogenous YAP/TAZ binding to TEAD1 but not TEAD1-NCOA2. TEAD1-Flag or TEAD1-NCOA2-Flag was expressed in HEK293T cells and immunoprecipitated with an anti-Flag antibody. Endogenous YAP/TAZ proteins were detected by anti-YAP/TAZ antibodies. (<bold>D</bold>) The activity of TBS-Luc reporter in HEK293T cells expressing YAP<sup>5SA</sup>, VGLL2-NCOA2, or TEAD1-NCOA2, with TEAD inhibitor CP1 (5 μM) treatment or co-expression of TEAD-ENR repressor construct. Data were expressed as mean ± SD. n=3; ****p&lt;0.0001. NS, no significance. (<bold>E</bold>) Schematic representation of TEAD-ENR. TEA DNA-binding domain (TEA) and Engrailed repressor domain (ENR). (<bold>F</bold>) Immunoblot analysis of TEAD-ENR expression in HEK293T cells. (<bold>G</bold>) Co-IP assays showing YAP/TAZ were not essential for VGLL2-NCOA2 binding to endogenous TEADs. VGLL2-NCOA2-HA was expressed in HEK293T cells with or without YAP/TAZ knockdown and immunoprecipitated with an anti-HA antibody. (<bold>H</bold>) Relative mRNA levels of <italic>CCN2</italic>, <italic>ANKRD1</italic>, and <italic>CCN1</italic> in HEK293T cells with YAP/TAZ knockdown and expressing VGLL2-NCOA2 or TEAD1-NCOA2. Data were expressed as mean ± SD. n=3; ****p&lt;0.0001.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Original western blot membranes corresponding to <xref ref-type="fig" rid="fig2">Figure 2A, B, C, F and G</xref> indicating the relevant bands.</title><p>The molecular weight markers are indicated.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98386-fig2-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>Original western blot membranes corresponding to <xref ref-type="fig" rid="fig2">Figure 2A, B, C, F and G</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98386-fig2-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98386-fig2-v1.tif"/></fig><p>To examine the TEAD regulation in VGLL2-NCOA2 and TEAD1-NCOA2-mediated transcription, we first utilized a small-molecule TEAD inhibitor, CP1, that was recently developed to inhibit TEAD auto-palmitoylation, leading to protein instability and transcriptional inactivation (<xref ref-type="bibr" rid="bib30">Li et al., 2020</xref>; <xref ref-type="bibr" rid="bib45">Sun et al., 2022</xref>). Upon treatment with the TEAD palmitoylation inhibitor CP1 in HEK293T cells transfected with YAP<sup>5SA</sup>, VGLL2-NCOA2, and TEAD1-NCOA2, we found that CP1 effectively inhibited YAP<sup>5SA</sup>- and VGLL2-NCOA2-induced transcriptional activation but had largely no effect on TEAD1-NCOA2-induced reporter activation (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). The inability of CP1 to inhibit TEAD1-NCOA2 activity is likely because the TEAD1-NCOA2 fusion does not contain the auto-palmitoylation sites in the C-terminal YAP-binding domain of TEAD1. To further explore TEAD dependence, we generated a TEAD fusion-dominant repressor, TEAD-ENR, which fuses its N-terminal TEA DNA-binding domain to a C-terminal Engrained repressor domain (<xref ref-type="fig" rid="fig2">Figure 2E and F</xref>). When co-expressed with YAP<sup>5SA</sup>, VGLL2-NCOA2, and TEAD1-NCOA2 in HEK293T cells, TEAD-ENR potently inhibited the transcriptional activation of all three proteins (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). These results from both the TEAD inhibitor and transcriptional repressor suggest that downstream TEAD activity and TEAD DNA binding are critical for both fusion proteins.</p><p>To further examine the involvement of YAP and TAZ in VGLL2-NCOA2- and TEAD1-NCOA2-induced transcription, we used lentiviral-based shRNA to knock down the expression of YAP and TAZ in HEK293T cells (<xref ref-type="fig" rid="fig2">Figure 2G</xref>). We showed that VGLL2-NCOA2 could bind to endogenous TEAD proteins at similar levels in both control and YAP/TAZ-knockdown HEK293T cells (<xref ref-type="fig" rid="fig2">Figure 2G</xref>), suggesting its association with TEADs does not require YAP/TAZ. Furthermore, we found that both VGLL2-NCOA2 and TEAD1-NCOA2 still robustly induced the transcription of the known TEAD target genes, including <italic>CCN1</italic>, <italic>CCN2</italic>, and <italic>ANKRD1</italic>, in HEK293T cells with YAP/TAZ knockdown (<xref ref-type="fig" rid="fig2">Figure 2H</xref>). Taken together, our data suggest that VGLL2-NCOA2- and TEAD1-NCOA2-induced transcriptional activation requires TEAD DNA binding but is YAP/TAZ independent.</p></sec><sec id="s2-3"><title>Characterization of VGLL2-NCOA2- and YAP-controlled transcriptional and chromatin landscapes</title><p>To understand the mechanism of how the fusion proteins may control chromatin landscapes and drive downstream transcription, we performed analyses of ATAC-seq, CUT&amp;RUN sequencing, and RNA-seq in HEK293T cells that ectopically expressed VGLL2-NCOA2 and compared them to the epigenetic and transcriptional programs controlled by YAP<sup>5SA</sup>.</p><p>By intersecting the datasets of ATAC-seq (assessing genome-wide chromatin accessibility regulated by VGLL2-NCOA2 and YAP<sup>5SA</sup>), CUT&amp;RUN (mapping both VGLL2-NCOA2 and YAP<sup>5SA</sup> binding sites across the genome), and RNA-seq (transcriptome profiling in VGLL2-NCOA2 and YAP<sup>5SA</sup>-expressing cells), we determined that VGLL2-NCOA2 and YAP controlled overlapping yet distinct chromatin landscapes and downstream transcriptional programs (<xref ref-type="fig" rid="fig3">Figure 3</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Characterization of VGLL2-NCOA2- and YAP-controlled transcriptional and chromatin landscapes.</title><p>(<bold>A</bold>) Intersection of ATAC-seq (n=2), RNA-seq (n=3), and CUT&amp;RUN (n=2) datasets in HEK293T cells expressing VGLL2-NCOA2 or YAP<sup>5SA</sup>. (<bold>B</bold>) Venn diagrams showing the overlaps of ATAC-seq peaks, CUT&amp;RUN peaks, and differentially regulated genes from RNA-seq in HEK293T cells expressing VGLL2-NCOA2 or YAP<sup>5SA</sup>. (<bold>C</bold>) KEGG pathway enrichment analysis of ATAC-seq peaks identified in HEK293T cells expressing VGLL2-NCOA2 or YAP<sup>5SA</sup>. The ‘Hippo signaling pathway’ is highlighted in red. (<bold>D</bold>) Distribution of CUT&amp;RUN binding sites for VGLL2-NCOA2 and YAP<sup>5SA</sup>. (<bold>E</bold>) Motif enrichment analysis of VGLL2-NCOA2 and YAP<sup>5SA</sup> CUT&amp;RUN Peaks. (<bold>F</bold>) Genomic tracks showing VGLL2-NCOA2 and YAP<sup>5SA</sup> occupancy at the <italic>CCN2</italic>, <italic>ANKRD1</italic>, and <italic>CCN1</italic> loci.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98386-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>ATAC-seq and CUT&amp;RUN data characterization in VGLL2-NCOA2 and YAP<sup>5SA</sup>-expressing cells.</title><p>(<bold>A</bold>) Heatmaps of TEAD-motif containing ATAC-seq peaks in HEK293T cells expressing VGLL2-NCOA2 or YAP<sup>5SA</sup>. (<bold>B</bold>) Distribution of ATAC-seq peaks in HEK293T cells expressing VGLL2-NCOA2 or YAP<sup>5SA</sup>. For VGLL2-NCOA2 ATAC-seq peaks, Promoter (≤ 1 kb) 50.57%, promoter (1–2 kb) 6.59%, 5′ UTR 0.13%, 3' UTR 1.44%, exon 1.52%, intron 18.39%, and distal and Intergenic 21.35%. For YAP<sup>5SA</sup> ATAC-seq peaks, promoter (≤ 1 kb) 51.4%, promoter (1–2 kb) 6.89%, 5′ UTR 0.13%, 3′ UTR 1.45%, exon 1.58%, intron 17.28%, and distal and intergenic 21.26%. n=2. (<bold>C</bold>) VGLL2-NCOA2 promotes chromatin accessibility. Scatter diagrams of ATAC-seq peaks show more upregulated (red) than downregulated (blue) in HEK293T cells transfected with VGLL2-NCOA2 or YAP<sup>5SA</sup>. (<bold>D</bold>) Heatmaps of VGLL2-NCOA2 and YAP<sup>5SA</sup> CUT&amp;RUN peaks. (<bold>E</bold>) VGLL2-NCOA2 and YAP genomic occupancy. Scatter diagrams showing more upregulated CUT&amp;RUN peaks (red) than downregulated CUT&amp;RUN peaks (blue) of VGLL2-NCOA2 and YAP<sup>5SA</sup>. (<bold>F</bold>) KEGG pathway enrichment analysis of VGLL2-NCOA2 and YAP<sup>5SA</sup> CUT&amp;RUN peaks. ‘Hippo signaling pathway’ is highlighted in red.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98386-fig3-figsupp1-v1.tif"/></fig></fig-group><p>In our ATAC-seq assay, the analysis of differentially accessible chromatin sites annotated to the nearest genes showed significant enrichment of Hippo pathway-related genes in both VGLL2-NCOA2 and YAP<sup>5SA</sup>-expressing cells (<xref ref-type="fig" rid="fig3">Figure 3A–C</xref>), suggesting that VGLL2-NCOA2 and YAP<sup>5SA</sup> likely drive open chromatin architecture in a shared set of genes. This is also consistent with our analysis of the genomic occupancy profiles of VGLL2-NCOA2 and YAP<sup>5SA</sup> defined by CUT&amp;RUN sequencing (<xref ref-type="fig" rid="fig3">Figure 3D-F</xref>). Annotation of CUT&amp;RUN peaks with respect to their nearest gene transcriptional start site (TSS) showed that both VGLL2-NCOA2 and YAP preferred to occupy distal genomic regions that are not in close proximity to the TSS (0–2 kb) (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). This is consistent with prior reports that YAP preferentially binds to distal enhancer regions (<xref ref-type="bibr" rid="bib63">Zanconato et al., 2015</xref>; <xref ref-type="bibr" rid="bib32">Liu et al., 2016</xref>) and indicates that the VGLL2-NCOA2 fusion protein also regulates downstream gene transcription through active enhancers.</p><p>In addition, de novo motif analysis of our CUT&amp;RUN datasets revealed that the TEAD binding sequence was among the most enriched motifs in both VGLL2-NCOA2 and YAP<sup>5SA</sup> CUT&amp;RUN peaks (<xref ref-type="fig" rid="fig3">Figure 3E</xref>), consistent with our observation that TEAD DNA binding was essential for transcriptional activation induced by the fusion proteins (<xref ref-type="fig" rid="fig2">Figure 2A–F</xref>). Interestingly, the AP1 motif was also enriched in VGLL2-NCOA2 CUT&amp;RUN peaks (<xref ref-type="fig" rid="fig3">Figure 3E</xref>), highlighting its proposed roles in TEAD-mediated transcription (<xref ref-type="bibr" rid="bib63">Zanconato et al., 2015</xref>; <xref ref-type="bibr" rid="bib32">Liu et al., 2016</xref>). Furthermore, we compared the binding profiles of the <italic>bona fide</italic> downstream target genes of VGLL2-NCOA2 and YAP identified in our CUT&amp;RUN analysis, <italic>CCN1</italic>, <italic>CCN2</italic>, and <italic>ANKRD1</italic>, and showed that VGLL2-NCOA2 and YAP occupied the same genomic regions in the loci of the three genes (<xref ref-type="fig" rid="fig3">Figure 3F</xref>). Our analyses demonstrated that VGLL2-NCOA2 and YAP control overlapping yet distinct chromatin landscapes and occupy a shared set of genomic regions, thereby driving downstream gene transcription.</p></sec><sec id="s2-4"><title>VGLL2-NCOA2 and TEAD1-NCOA2 engage EP300 epigenetic regulators</title><p>In addition to their YAP/TAZ independence, the distinct nature of transcriptional and chromatin landscapes controlled by VGLL2-NCOA2 and YAP prompted us to hypothesize that the fusion proteins might utilize different sets of epigenetic/transcriptional regulators to modify chromatin and drive gene expression. To this end, we adopted a proximity-labeling proteomics approach called BioID (<xref ref-type="bibr" rid="bib26">Kim and Roux, 2016</xref>) to identify the potential binding partners of VGLL2-NCOA2 and TEAD1-NCOA2 and compared them to YAP and TAZ.</p><p>In our BioID proteomics screens, we tagged YAP<sup>5SA</sup>, TAZ<sup>4SA</sup>, VGLL2-NCOA2, and TEAD1-NCOA2 with BirA* (a promiscuous version of the biotin ligase BirA) and used them as baits to probe the proteomes associated with these proteins (<xref ref-type="fig" rid="fig4">Figure 4A</xref>, <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>). By intersecting the hits associated with YAP/TAZ or VGLL2-NCOA2/TEAD1-NCOA2, we found that TEAD proteins were among the few proteins associated with all four proteins, providing validation of our BioID datasets (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Focusing on epigenetic and transcriptional regulators identified in the screens, we found that CREBBP (CBP) and EP300 (P300) were among the hits specifically associated with VGLL2-NCOA2 and TEAD1-NCOA2 in the BioID assays (<xref ref-type="fig" rid="fig4">Figure 4A</xref>).</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>VGLL2-NCOA2 and TEAD1-NCOA2 engage EP300 epigenetic regulators.</title><p>(<bold>A</bold>) Diagram showing the BioID proteomic analyses of BirA*-VGLL2-NCOA2, BirA*-TEAD1-NCOA2, BirA*-YAP<sup>5SA</sup>, and BirA*-TAZ<sup>4SA</sup>. (<bold>B</bold>) Co-IP assays showing endogenous EP300 binding to VGLL2-NCOA2 and TEAD1-NCOA2 but not YAP<sup>5SA</sup>. (<bold>C</bold>) KEGG enrichment analysis of EP300 CUT&amp;RUN peaks in control HEK293T cells and HEK293T cells expressing VGLL2-NCOA2 or TEAD1-NCOA2. The ‘Hippo signaling pathway’ is highlighted in red. (<bold>D</bold>) Motif enrichment analysis of EP300 CUT&amp;RUN peaks in control HEK293T cells and HEK293T cells expressing VGLL2-NCOA2 or TEAD1-NCOA2. (<bold>E</bold>) Genomic tracks showing EP300 occupancy at the <italic>CCN1</italic>, <italic>ANKRD1</italic>, <italic>CCN2</italic>, and <italic>CREB3</italic> loci in control HEK293T cells and HEK293T cells expressing VGLL2-NCOA2 or TEAD1-NCOA2.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Original western blot membranes corresponding to <xref ref-type="fig" rid="fig4">Figure 4B</xref> indicating the relevant bands.</title><p>The molecular weight markers are indicated.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98386-fig4-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><label>Figure 4—source data 2.</label><caption><title>Original western blot membranes corresponding to <xref ref-type="fig" rid="fig4">Figure 4B</xref> indicating the relevant bands.</title><p>The molecular weight markers are indicated.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98386-fig4-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98386-fig4-v1.tif"/></fig><p>The closely related histone acetyltransferases CREBBP and EP300, commonly referred to as CREBBP/EP300, are known for their function to induce histone H3 lysine 27 acetylation (H3K27ac) at the promoter and enhancer regions, thereby activating gene transcription (<xref ref-type="bibr" rid="bib37">Ogryzko et al., 1996</xref>; <xref ref-type="bibr" rid="bib4">Bannister and Kouzarides, 1996</xref>; <xref ref-type="bibr" rid="bib55">Waddell et al., 2021</xref>; <xref ref-type="bibr" rid="bib21">Hogg et al., 2021</xref>). More importantly, CREBBP/EP300 has been reported to form a complex with the NCOA family proteins that play a critical role in the regulation of nuclear receptors-mediated transcription (<xref ref-type="bibr" rid="bib55">Waddell et al., 2021</xref>; <xref ref-type="bibr" rid="bib61">Yi et al., 2021</xref>). It is consistent with our proteomics data that the C-terminal NCOA part of VGLL2-NCOA2 and TEAD1-NCOA2 fusions interacted with CREBBP/EP300 (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Interestingly, our motif enrichment analysis identified CREB motif as specifically enriched among VGLL2-NCOA2 CUT&amp;RUN peaks, but not in YAP<sup>5SA</sup> peaks (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). CREB is a known transcription factor interacting with CREBBP/EP300 (<xref ref-type="bibr" rid="bib12">Chrivia et al., 1993</xref>), further supporting the notion that VGLL2-NCOA2 and TEAD1-NCOA2 fusion proteins might recruit CREBBP/EP300. In addition, the activity of CREBBP/EP300 has been implicated in several types of human cancers (<xref ref-type="bibr" rid="bib55">Waddell et al., 2021</xref>; <xref ref-type="bibr" rid="bib21">Hogg et al., 2021</xref>). Thus, we set out to further examine the interaction between CREBBP/EP300 and the fusion proteins and how it may affect downstream transcriptional activation.</p><p>We performed the co-IP analysis in HEK293T cells overexpressing VGLL2-NCOA2, TEAD1-NCOA2, and YAP<sup>5SA</sup> and demonstrated that VGLL2-NCOA2 and TEAD1-NCOA2, but not YAP<sup>5SA</sup>, were strongly associated with endogenous EP300 proteins (<xref ref-type="fig" rid="fig4">Figure 4B</xref>), suggesting the specific engagement of EP300 by fusion proteins. To further examine the potential functional regulation of fusion protein-mediated transcription by CREBBP/EP300, we carried out the CUT&amp;RUN sequencing analysis to map EP300 genomic occupancy sites in control and VGLL2-NCOA2- or TEAD1-NCOA2-expressing HEK293T cells (<xref ref-type="fig" rid="fig4">Figure 4C–E</xref>). Pathway enrichment analysis of EP300 binding peaks annotated by the nearest genes showed significant enrichment of Hippo pathway-related genes in both VGLL2-NCOA2 and TEAD1-NCOA2 expressing cells but not in the control cells (<xref ref-type="fig" rid="fig4">Figure 4C</xref>), suggesting that VGLL2-NCOA2 and TEAD1-NCOA2 fusion proteins recruit the CREBBP/EP300 complex to a specific set of genes, likely including the TEAD-dependent downstream target genes. In keeping with this result, our de novo motif analysis also revealed that TEAD and AP1 binding sequences were among the top-ranking motifs identified in EP300 occupied genomic sites, specifically in VGLL2-NCOA2- and TEAD1-NCOA2-expressing cells (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). Interestingly, we noticed that the CREB binding sequence was one of the top-ranking motifs identified in EP300 peaks in both control and VGLL2-NCOA2/TEAD1-NCOA2-expressing cells (<xref ref-type="fig" rid="fig4">Figure 4D</xref>), consistent with the notion that the CREB family transcription factors are the downstream binding partners of CREBBP/EP300, further validating our CUT&amp;RUN datasets. Upon further examining the binding profiles of EP300 in the loci of <italic>CCN1</italic>, <italic>CCN2</italic>, and <italic>ANKRD1</italic>, we showed that EP300 bound to these loci in VGLL2-NCOA2/TEAD1-NCOA2-expressing cells, but not in control cells (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). More importantly, EP300 bound to the same genomic regions that were also occupied by VGLL2-NCOA2 identified in VGLL2-NCOA2 CUT&amp;RUN assay (<xref ref-type="fig" rid="fig3">Figure 3F</xref>). As a control, we showed that EP300 occupied the genomic sites within the <italic>CREB3</italic> locus in cells with or without the expression of the fusion proteins (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). Taken together, these data suggest that VGLL2-NCOA2 and TEAD1-NCOA2 fusion proteins interact with CREBBP/EP300, recruiting them to promote TEAD target gene expression.</p></sec><sec id="s2-5"><title>EP300 is required for VGLL2-NCOA2 and TEAD1-NCOA2-induced tumorigenesis</title><p>To test whether VGLL2-NCOA2- and TEAD1-NCOA2-mediated sarcomagenesis is CREBBP/EP300 dependent, we utilized the C2C12 myoblast transformation models both in vitro and in vivo. Prior reports have demonstrated that VGLL2-NCOA2 can induce oncogenic transformation of C2C12 cells in cell culture and allograft mouse tumor models (<xref ref-type="bibr" rid="bib57">Watson et al., 2023</xref>). However, it is not known whether VGLL2-NCOA2 or TEAD1-NCOA2 can induce TEAD-mediated transcription and whether EP300 is functionally relevant in these models.</p><p>We first demonstrated that VGLL2-NCOA2 binds to EP300 via its C-terminal NCOA2 part using co-immunoprecipitation assays (<xref ref-type="fig" rid="fig5">Figure 5A</xref>), highlighting the essential role of the NCOA2 part of the fusion proteins in recruiting EP300 to induce downstream transcription and tumorigenesis. We found that the expression of both VGLL2-NCOA2 and TEAD1-NCOA2 fusion proteins was able to robustly induce the transcription of the known Tead target genes, <italic>Ccn1</italic>, <italic>Ccn2</italic>, and <italic>Ankrd1</italic>, in C2C12 cells (<xref ref-type="fig" rid="fig5">Figure 5B–D</xref>). By utilizing a potent EP300 small-molecule inhibitor, A485, which inhibits CREBBP/EP300 activity both in vitro and in vivo (<xref ref-type="bibr" rid="bib21">Hogg et al., 2021</xref>; <xref ref-type="bibr" rid="bib29">Lasko et al., 2017</xref>), we showed that EP300 inhibition by A485 treatment strongly inhibited transcriptional upregulation of <italic>Ccn1, Ccn2</italic>, and <italic>Ankrd1</italic> induced by the fusion proteins (<xref ref-type="fig" rid="fig5">Figure 5B–D</xref>). In contrast, A485 was not able to strongly block YAP<sup>5SA</sup>-induced Tead target gene expression in C2C12 cells (<xref ref-type="fig" rid="fig5">Figure 5B–D</xref>), suggesting that CREBBP/EP300 is required for VGLL2-NCOA2 and TEAD1-NCOA2-dependent gene expression but is largely dispensable for YAP/TAZ-induced target gene transcription. Furthermore, we demonstrated that VGLL2-NCOA2 and TEAD1-NCOA2 were also able to induce colony formation of C2C12 cells in soft agar (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). More importantly, A485 treatment markedly reduced the numbers and sizes of the soft agar colonies induced by TEAD1-NCOA2 and VGLL2-NCOA2 but not YAP<sup>5SA</sup> (<xref ref-type="fig" rid="fig5">Figure 5F and G</xref>), which is consistent with the differential effect of EP300 inhibition on downstream gene transcription induced by the fusion proteins or YAP (<xref ref-type="fig" rid="fig5">Figure 5B–D</xref>).</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>EP300 is required for VGLL2-NCOA2- and TEAD1-NCOA2-induced tumorigenesis in vitro.</title><p>(<bold>A</bold>) Co-IP assays showing the NCOA2 fusion part of VGLL2-NCOA2 was essential for EP300 binding. VGLL2-NCOA2-V5, VGLL2-NCOA2<sup>∆NCOA2</sup>-V5, and VGLL2-NCOA2<sup>∆VGLL2</sup>-V5 were expressed in HEK293T cells and immunoprecipitated using an anti-V5 antibody. Endogenous EP300 proteins were detected by anti-EP300 antibody. (<bold>B–D</bold>) mRNA levels of <italic>Ccn2</italic>, <italic>Ankrd1</italic>, and <italic>Ccn1</italic> in C2C12 cells expressing YAP<sup>5SA</sup>, VGLL2-NCOA2, or TEAD1-NCOA2 with or without treatment of A485 (5 μM). Data were expressed as mean ± SD. n=3; ****p&lt;0.0001. NS, no significance. (<bold>E</bold>) Representative image of colony formation of C2C12 cells expressing YAP<sup>5SA</sup>, VGLL2-NCOA2, or TEAD1-NCOA2 with or without treatment of A485 (5 μM) for 2 weeks. Scale bars, 100 μm. (<bold>F, G</bold>) Colony size (<bold>F</bold>) and number of colonies (<bold>G</bold>) formed by C2C12 cells expressing YAP<sup>5SA</sup>, VGLL2-NCOA2, or TEAD1-NCOA2 with or without treatment of A485 (5 μM). Data were expressed as mean ± SD. **p&lt;0.01; ****p&lt;0.0001. NS, no significance.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Original western blot membranes corresponding to <xref ref-type="fig" rid="fig5">Figure 5A</xref> indicating the relevant bands.</title><p>The molecular weight markers are indicated.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98386-fig5-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata2"><label>Figure 5—source data 2.</label><caption><title>Original western blot membranes corresponding to <xref ref-type="fig" rid="fig5">Figure 5A</xref> indicating the relevant bands.</title><p>The molecular weight markers are indicated.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98386-fig5-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98386-fig5-v1.tif"/></fig><p>To examine the functional dependence of CREBBP/EP300 in tumorigenesis in vivo, we took advantage of the C2C12 allograft tumor models and demonstrated that both VGLL2-NCOA2 and TEAD1-NCOA2-expressing C2C12 cells were able to generate aggressive tumors when allografted into nude mice, leading to termination of tumor-bearing mice at around 30 days post-injection. These VGLL2-NCOA2- and TEAD1-NCOA2-expressing tumors were highly proliferative, measured by Ki67 staining, but exhibited heterogeneous expression of Desmin (<xref ref-type="fig" rid="fig6">Figure 6A and B</xref>). In addition, we found that EP300 inhibition by A485 significantly blocked the tumor growth in both VGLL2-NCOA2 and TEAD1-NCOA2 allograft tumor models (<xref ref-type="fig" rid="fig6">Figure 6C and D</xref>), and A485 treatment markedly decreased the proliferation of tumor cells (<xref ref-type="fig" rid="fig6">Figure 6E and F</xref>) and the transcription of the target genes, including <italic>Ccn1</italic>, <italic>Ccn2</italic>, and <italic>Ankrd1</italic> (<xref ref-type="fig" rid="fig6">Figure 6G and H</xref>), in both VGLL2-NCOA2 and TEAD1-NCOA2 tumor models. Together, these data, both in vitro and in vivo, suggest that the CREBBP/EP300 factors are essential for tumorigenesis induced by VGLL2-NCOA2 and TEAD1-NCOA2 fusion proteins.</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>EP300 is essential for VGLL2-NCOA2- and TEAD1-NCOA2-induced tumorigenesis in vivo.</title><p>(<bold>A</bold>) Representative H&amp;E and IHC staining of Desmin and Ki67 in C2C12-control allograft, C2C12-VGLL2-NCOA2 tumor allograft, and C2C12-TEAD1-NCOA2 tumor allograft. Scale bars, 200 μm. (<bold>B</bold>) Immunoblot analysis of VGLL2-NCOA2-FLAG and TEAD1-NCOA2-FLAG expression in C2C12 cells, detected by an anti-FLAG antibody. (<bold>C, D</bold>) Allograft leg volume of C2C12-VGLL2-NCOA2 (<bold>C</bold>) and C2C12-TEAD1-NCOA2 (<bold>D</bold>) after intramuscular injection into the leg of Nude mice with or without intraperitoneal injection of A485 (100 mg/kg). The error bars represent the mean leg volume ± SEM. n=6. ****p&lt;0.0001. (<bold>E</bold>) Representative H&amp;E and IHC staining of Ki67 in C2C12-VGLL2-NCOA2 and C2C12-TEAD1-NCOA2 tumor allografts with or without A485 (100 mg/kg) treatment. Scale bars, 200 μm. (<bold>F</bold>) Percentage of Ki67-positive cells in (<bold>E</bold>). Data were expressed as mean ± SD. n=6; ***p&lt;0.001. (<bold>G, H</bold>) mRNA levels of <italic>Ccn2</italic>, <italic>Ankrd1</italic>, and <italic>Ccn1</italic> in C2C12-VGLL2-NCOA2 and C2C12-TEAD1-NCOA2 tumor allografts with or without A485 (100 mg/kg) treatment. Data were expressed as mean ± SD. **p&lt;0.01; ***p&lt;0.001; ****p&lt;0.0001.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Original western blot membranes corresponding to <xref ref-type="fig" rid="fig6">Figure 6B</xref> indicating the relevant bands.</title><p>The molecular weight markers are indicated.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98386-fig6-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig6sdata2"><label>Figure 6—source data 2.</label><caption><title>Original western blot membranes corresponding to <xref ref-type="fig" rid="fig6">Figure 6B</xref> indicating the relevant bands.</title><p>The molecular weight markers are indicated.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98386-fig6-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98386-fig6-v1.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Misregulation of YAP and TAZ, including protein upregulation, nuclear accumulation, and fusion translocation, has emerged as a major mechanism underlying Hippo signaling involvement in tumorigenesis (<xref ref-type="bibr" rid="bib38">Piccolo et al., 2023</xref>; <xref ref-type="bibr" rid="bib52">Thompson, 2020</xref>; <xref ref-type="bibr" rid="bib18">Franklin et al., 2023</xref>; <xref ref-type="bibr" rid="bib46">Szulzewsky et al., 2021</xref>; <xref ref-type="bibr" rid="bib19">Garcia et al., 2022</xref>). In this work, our characterization of VGLL2-NCOA2 and TEAD1-NCOA2 fusion proteins generated by recurrent rearrangement in scRMS provides a distinct mechanism of oncogenic transformation that is related to the Hippo pathway but independent of the YAP/TAZ function.</p><p>Among the members of the VGLL family proteins, VGLL4 stands out as a <italic>bona fide</italic> transcriptional repressor for YAP/TAZ via its two TEAD-binding TDU domain. The other members of the family, VGLL1-3, contain a single TDU domain, and it is not fully understood whether and how they regulate YAP/TAZ-TEAD transcriptional output. Unlike YAP, TAZ, and VGLL2-NCOA2 fusion, VGLL2 itself does not appear to be a strong activator of TEAD-mediated transcription, even when overexpressed in cells. In both VGLL2-NCOA2 and TEAD1-NCOA2 fusions, the lack of NCOA2 N-terminal domains suggests that they are unlikely to be subject to downstream regulation by nuclear receptors, the canonical binding partners of the NCOA/SRC transcriptional regulators (<xref ref-type="bibr" rid="bib61">Yi et al., 2021</xref>). Our previous work showed that the NCOA family proteins are associated with the YAP/TAZ-TEAD transcriptional machinery (<xref ref-type="bibr" rid="bib32">Liu et al., 2016</xref>); however, the presence of YAP/TAZ in the complex appears to be dominant in directing TEAD-mediated transcriptional activation in the normal context. Clearly, the C-terminal NCOA2 TADs render robust transcriptional activity in both VGLL2-NCOA2 and TEAD1-NCOA2 fusions, underlying their oncogenic activity that bypasses the requirement for YAP/TAZ.</p><p>Our data showed that VGLL2-NCOA2 and TEAD1-NCOA2 fusions converge on the TEAD family transcription factors or TEAD-mediated genomic occupancy, highlighting the central role of TEADs in Hippo-related tumorigenesis. The small-molecule TEAD inhibitors are currently undergoing preclinical or clinical evaluation for cancer treatment (<xref ref-type="bibr" rid="bib40">Pobbati et al., 2023</xref>). These inhibitors target TEAD auto-palmitoylation, an enzymatic-like activity carried out by the C-terminal YAP/TAZ binding domain of the TEAD proteins (<xref ref-type="bibr" rid="bib30">Li et al., 2020</xref>; <xref ref-type="bibr" rid="bib40">Pobbati et al., 2023</xref>; <xref ref-type="bibr" rid="bib10">Chan et al., 2016</xref>; <xref ref-type="bibr" rid="bib22">Holden et al., 2020</xref>; <xref ref-type="bibr" rid="bib25">Kaneda et al., 2020</xref>; <xref ref-type="bibr" rid="bib50">Tang et al., 2021</xref>; <xref ref-type="bibr" rid="bib23">Hu et al., 2022</xref>). The lack of YAP/TAZ binding domain in TEAD1 fusion results in the inability of the TEAD palmitoylation inhibitor to suppress gene transcription, suggesting the potential limitation of TEAD palmitoylation inhibitors in tumors carrying TEAD rearrangements. In addition, current TEAD small-molecule inhibitors are generally thought to allosterically affect the binding between YAP/TAZ and TEADs. How these inhibitors may affect TEAD interaction with VGLL or VGLL fusion proteins requires further investigation.</p><p>Our identification of CREBBP/EP300 as specific epigenetic regulators for VGLL2-NCOA2 and TEAD1-NCOA2 proteins provides a molecular mechanism underlying their YAP/TAZ-independent regulation of transcription and tumorigenesis. In another recurrent <italic>VGLL2</italic> rearrangement identified in scRMS, <italic>CITED2</italic>, the 3′ partner in the VGLL2-CITED2 fusion, is a known transcriptional regulator associated with CREBBP/EP300 (<xref ref-type="bibr" rid="bib1">Alaggio et al., 2016</xref>; <xref ref-type="bibr" rid="bib5">Bhattacharya et al., 1999</xref>; <xref ref-type="bibr" rid="bib3">Bamforth et al., 2001</xref>). It is possible that the VGLL2-CITED2 fusion also mediates YAP/TAZ-independent TEAD-dependent transcriptional activation by engaging CREBBP/EP300. Our data using small-molecular CREBBP/EP300 inhibitors both in vitro and in vivo further supports its critical role in VGLL and TEAD fusion protein-mediated oncogenic transformation. This finding may also provide a potential therapeutic strategy for scRMS characterized by these fusion proteins, as well as a range of other tumors carrying NCOA1/2/3 rearrangements, including uterine sarcoma (<xref ref-type="bibr" rid="bib36">Niu et al., 2023</xref>), mesenchymal chondrosarcoma (<xref ref-type="bibr" rid="bib56">Wang et al., 2012</xref>; <xref ref-type="bibr" rid="bib49">Tanaka et al., 2023</xref>), soft tissue angiofibroma (<xref ref-type="bibr" rid="bib24">Jin et al., 2012</xref>; <xref ref-type="bibr" rid="bib60">Yamashita et al., 2023</xref>), ovarian sex cord tumors (<xref ref-type="bibr" rid="bib20">Goebel et al., 2020</xref>; <xref ref-type="bibr" rid="bib33">Lu et al., 2023</xref>), leukemia (<xref ref-type="bibr" rid="bib44">Strehl et al., 2008</xref>), colon cancer (<xref ref-type="bibr" rid="bib62">Yu et al., 2016</xref>), and ependymoma (<xref ref-type="bibr" rid="bib51">Tauziède-Espariat et al., 2021</xref>; <xref ref-type="bibr" rid="bib53">Tomomasa et al., 2021</xref>).</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Flag (mouse monoclonal)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">MA1-91878</td><td align="left" valign="bottom">CUT&amp;RUN (0.5 μg)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-GAPDH (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="char" char="." valign="bottom">2118</td><td align="left" valign="bottom">WB (1:10,000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-YAP/TAZ (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="char" char="." valign="bottom">8418</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-panTEAD (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="char" char="." valign="bottom">13295</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-V5 (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="char" char="." valign="bottom">13202</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-EP300 (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="char" char="." valign="bottom">86377</td><td align="left" valign="bottom">WB (1:1000); CUT&amp;RUN (0.5 μg)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Flag (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="char" char="." valign="bottom">2368</td><td align="left" valign="bottom">WB (1:1000); IP (1:50)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Flag (mouse monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">F9291</td><td align="left" valign="bottom">WB (1:1000); IP (1:50)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-HA (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="char" char="." valign="bottom">3724</td><td align="left" valign="bottom">WB (1:1000); IP (1:50)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-HA (mouse monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="char" char="." valign="bottom">2367</td><td align="left" valign="bottom">WB (1:1000); IP (1:50)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">HRP-conjugated secondary antibodies</td><td align="left" valign="bottom">Jackson Laboratories</td><td align="left" valign="bottom"/><td align="left" valign="bottom">WB (1:2000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Ki67 (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="char" char="." valign="bottom">12202</td><td align="left" valign="bottom">IHC (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Desmin (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="char" char="." valign="bottom">5332</td><td align="left" valign="bottom">IHC (1:100)</td></tr><tr><td align="left" valign="bottom">Strain, strain background (NU/J nude mice)</td><td align="left" valign="bottom">NU/J nude mice</td><td align="left" valign="bottom">The Jackson Laboratory</td><td align="char" char="." valign="bottom">002019</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">HEK293T</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">CRL-3216</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (mouse-<italic>sapiens</italic>)</td><td align="left" valign="bottom">C2C12</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">CRL-1772</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">A485</td><td align="left" valign="bottom">SelleckChem</td><td align="left" valign="bottom">S8740</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Streptavidin Sepharose beads</td><td align="left" valign="bottom">GE Healthcare</td><td align="char" char="." valign="bottom">17511301</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">SignalStain Antibody Diluent</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="char" char="." valign="bottom">8112</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Lipofectamine 2000</td><td align="left" valign="bottom">Invitrogen</td><td align="char" char="." valign="bottom">11668019</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">CP1</td><td align="left" valign="bottom">MCE</td><td align="left" valign="bottom">HY-139330</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">CUTANA ChIC/CUT&amp;RUN Kit</td><td align="left" valign="bottom">EpiCypher</td><td align="char" char="ndash" valign="bottom">14-1048</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">CUT&amp;RUN Library Prep Kit</td><td align="left" valign="bottom">EpiCypher</td><td align="char" char="ndash" valign="bottom">14-1001</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">RNeasy Mini Kit</td><td align="left" valign="bottom">QIAGEN</td><td align="char" char="." valign="bottom">74104</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Vectastain Elite ABC kit</td><td align="left" valign="bottom">Vector Laboratories</td><td align="left" valign="bottom">PK-6105</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">In-Fusion HD Cloning</td><td align="left" valign="bottom">Clontech</td><td align="left" valign="bottom">Clontech: 639647</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">commercial assay or kit</td><td align="left" valign="bottom">Dual-luciferase reporter kit</td><td align="left" valign="bottom">Promega</td><td align="left" valign="bottom">E1910</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">iTaq Universal One-Step RT-qPCR Kit</td><td align="left" valign="bottom">Bio-Rad</td><td align="char" char="." valign="bottom">1725150</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">BeyoClick EdU Cell Proliferation Kit with Alexa Fluor 488</td><td align="left" valign="bottom">Beyotime</td><td align="left" valign="bottom">C0071</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">iTaq Universal One-Step RT-qPCR Kit</td><td align="left" valign="bottom"> Bio-Rad</td><td align="char" char="." valign="bottom">1725150</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom"><italic>GAPDH</italic>-F'</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">GGAGCGAGATCCCTCCAAAAT</named-content></td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom"><italic>GAPDH</italic>-R'</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">GGCTGTTGTCATACTTCTCATGG</named-content></td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom"><italic>CCN2</italic>-F'</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">CAGCATGGACGTTCGTCTG</named-content></td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom"><italic>CCN2</italic>-R'</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">AACCACGGTTTGGTCCTTGG</named-content></td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom"><italic>ANKRD1</italic>-F'</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">GCCTACGTTTCTGAAGGCTG</named-content></td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom"><italic>ANKRD1</italic>-R'</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">GTGGATTCAAGCATATCACGGAA</named-content></td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom"><italic>CCN1</italic>-F'</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">CAGGACTGTGAAGATGCGGT</named-content></td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom"><italic>CCN1</italic>-R'</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">GCCTGTAGAAGGGAAACGCT</named-content></td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom"><italic>Actb</italic>-F'</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">GTGACGTTGACATCCGTAAAGA</named-content></td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom"><italic>Actb</italic>-R'</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">GCCGGACTCATCGTACTCC</named-content></td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom"><italic>Ccn2</italic>-F'</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">GACCCAACTATGATGCGAGCC</named-content></td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom"><italic>Ccn2</italic>-R'</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">CCCATCCCACAGGTCTTAGAAC</named-content></td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom"><italic>Ankrd1</italic>-F'</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">GGATGTGCCGAGGTTTCTGAA</named-content></td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom"><italic>Ankrd1</italic>-R'</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">GTCCGTTTATACTCATCGCAGAC</named-content></td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom"><italic>Ccn1</italic>-F'</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">TAAGGTCTGCGCTAAACAACTC</named-content></td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom"><italic>Ccn1</italic>-R'</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">CAGATCCCTTTCAGAGCGGT</named-content></td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Cell lines, transfection, lentiviral infections and luciferase reporter assays</title><p>HEK293T (cat. CRL-3216, ATCC, Manassas, VA, USA) and C2C12 (cat. CRL-1772, ATCC) cells were cultured in DMEM supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. Transfection in HEK293T cells was performed using Lipofectamine 2000 (cat. 11668019, Invitrogen, Waltham, MA, USA). For luciferase reporter assays, HEK293T cells were transfected with the luciferase reporter construct TBS-Luc (8XGTIIC-Luc, cat. 34615, Addgene, 8xGTIIC-luc was a gift from Stefano Piccolo), and the expression vectors for YAP<sup>5SA</sup>, TAZ<sup>4SA</sup>, VGLL2, NCOA2, TEAD1, TEAD-ENR, VGLL2-NCOA2, VGLL2-NCOA2<sup>∆VGLL2</sup>, VGLL2-NCOA2<sup>∆NCOA2</sup>, and TEAD1-NCOA2 (generated by and purchased from GenScript, Piscataway, NJ, USA; and GentleGen, Suzhou, Jiangsu Province, China) and pCMV-Renilla luciferase. Luciferase activities were conducted 24 hours after transfection in the cells treated with or without the TEAD inhibitor CP1 (5 μM for 24 hours) using the dual-luciferase reporter kit (cat. E1910, Promega, Madison, WI, USA). Assays were conducted in triplicates and quantified using PerkinElmer EnVision plate reader. For lentiviral infection, pLKO or pLX-based constructs expressing VGLL2-NCOA2, TEAD1-NCOA2, or shRNAs against YAP (5′-<named-content content-type="sequence">CCGGAAGCTTTGAGTTCTGACATCCCTCGAGGGATGTCAGAACTCAAAGCTTTTTTTC</named-content>-3', cat. 27368, Addgene, pLKO1-shYAP1 was a gift from Kunliang Guan) or TAZ (TRCN0000019470, purchased from Sigma, St. Louis, MO, USA) were transfected along with the packaging plasmids into growing HEK293T cells. Viral supernatants were collected 48 hours after transfection, and target cells were infected in the presence of polybrene and underwent selection with puromycin for 4–5 days. All cell lines used in this study were authenticated by short tandem repeat (STR) profiling and confirmed to be free of Mycoplasma contamination using a Mycoplasma detection assay.</p></sec><sec id="s4-2"><title>Protein immunoprecipitation and western blot</title><p>Cultured HEK293T cells were lysed in lysis buffer (50 mM Tris–HCl, pH 7.4, 150 mM NaCl, 0.5 mM EDTA, 1% Triton X-100, phosphatase inhibitor cocktail, cOmplete EDTA-free protease inhibitors cocktail) for 30 minutes at 4°C. The supernatants of the extracts were then used for the immunoprecipitation and western blot following the protocols described previously (<xref ref-type="bibr" rid="bib13">Cotton et al., 2017</xref>). The primary antibodies used in these assays were: GAPDH (cat. 2118, 1:5000, Cell Signaling Technology, Danvers, MA, USA), YAP/TAZ (cat. 8418, 1:1000, Cell Signaling Technology), panTEAD (cat. 13295, 1:1000, Cell Signaling Technology), V5-tag (cat. 13202, 1:1000, Cell Signaling Technology), EP300 (cat. 86377, 1:1000, Cell Signaling Technology), Flag-tag (cat. 2368, 1:1000, Cell Signaling Technology and cat. F9291, 1:1000, Sigma), and HA-tag (cat. 3724 and cat. 2367, 1:1000, Cell Signaling Technology). HRP-conjugated secondary antibodies used for detection were obtained from Jackson Laboratories (Sacramento, CA, USA).</p></sec><sec id="s4-3"><title>Quantitative RT-PCR (qPCR)</title><p>Total RNA was extracted using the RNeasy Mini Kit (cat. 74104, QIAGEN, Germantown, MD, USA). Gene expression was quantified using the iTaq Universal One-Step RT-qPCR Kit (cat. 1725150, Bio-Rad, Hercules, CA, USA) in Applied Biosystems and normalized to <italic>GAPDH</italic> or <italic>Actb</italic>. The primers used in this study are provided in the Key Resources Table. qPCR experiments were performed in triplicate, with average cycle threshold (Ct) values from three independent reactions used for analysis.</p></sec><sec id="s4-4"><title>RNA sequencing (RNA-seq)</title><p>Total RNA was isolated with the RNeasy Mini Kit (cat. 74104, QIAGEN). The integrity of the isolated RNA and RNA-seq libraries was analyzed by Novogene. All libraries had at least 50 million reads sequenced (150 bp paired-end). The correlation between gene expression changes was performed using Pearson’s correlation analysis. The p-values of gene changes in control groups compared with the experimental group were determined by Student’s <italic>t</italic>-test. Plots of correlation between fold change were generated using the ggplot2 package in R. Principal component analysis was determined and plotted using the M3C package in R. Gene Set Enrichment Analysis was performed using GSEA software. We performed RNA-seq in triplicate for each condition, and each replicate was independently processed and analyzed.</p></sec><sec id="s4-5"><title>Cleavage under targets and release using nuclease (CUT&amp;RUN)</title><p>CUT&amp;RUN was performed using the EpiCypher kit (cat. 14-1048, EpiCypher, Durham, NC, USA). Approximately 0.5 million cells were used for each reaction. In brief, HEK293T cells expressing YAP<sup>5SA</sup> or VGLL2-NCOA2, or TEAD1-NCOA2 were attached to preactivated ConA beads for 10 minutes at room temperature. Then, 0.5 μg of antibodies against Flag (cat. MA1-91878, Invitrogen) or EP300 (cat. 86377, Cell Signaling Technology) as well as control IgG were added to the reactions and incubated overnight at 4°C. The cells were incubated with pAG-MNase for 10 minutes at room temperature prior to activation by calcium chloride. Subsequently, the cells were incubated at 4°C for 2 hours prior to the addition of stop buffer. DNA was purified for library construction using a CUT&amp;RUN Library Prep Kit (cat. 14-1001, EpiCypher). Illumina HiSeq sequencing of approximately 10 million paired-end 150 bp reads was performed at Novogene. MACS2 software (v2.2.7.1) was used for peak calling. Deeptools software (v3.5.1) was used to plot heatmaps of the distribution of reads around TSS. Homer software (v4.11) was used to identify motifs. MANorm2 software (v1.2.0) was used to identify differentially enriched regions between two samples and/or two groups of samples. The scatter plot of the comparison of the two groups of samples is plotted according to the standardized expression mean. The enriched peaks were visualized in IGV (v2.4.10) software. GO and KEGG Pathway analysis were performed based on the promoter enriched peaks associated genes by the ClusterProfiler R packages (v3.18.1). CUT&amp;RUN assays were performed in duplicate for each condition and each replicate was independently processed and analyzed.</p></sec><sec id="s4-6"><title>Assay for transposase-accessible chromatin (ATAC-seq)</title><p>ATAC-seq library construction was performed as previously reported (<xref ref-type="bibr" rid="bib7">Buenrostro et al., 2013</xref>; <xref ref-type="bibr" rid="bib2">Bajic et al., 2018</xref>). Briefly, nuclei were extracted from HEK293T cells expressing GFP or VGLL2-NCOA2, and the nuclei pellet was resuspended in the Tn5 transposase reaction mix. The transposition reaction was incubated at 37°C for 30 minutes. Equimolar Adapter 1 and Adapter 2 were added after transposition, and PCR was then performed to amplify the library. After PCR amplification, libraries were purified with AMPure beads. The library was checked with Qubit and real-time PCR for quantification, and bioanalyzer for size distribution detection. Quantified libraries were pooled and sequenced on Illumina platforms, according to the effective library concentration and data amount required. ATAC-seq bioinformatics data analysis was performed following Harvard FAS Informatics ATAC-seq Guidelines. Briefly, Genrich software (v1.30.3) was used for peak calling and blacklist regions were removed. Deeptools software (v3.5.1) was used to plot heatmaps of the distribution of reads around TSS. ChIPseeker R package (v1.30.3) was used to annotate the enriched peaks. Homer software (v4.11) was used to identify motifs. MANorm2 R package was used to perform differentially enriched region analysis between two groups of samples. The scatter plot of the comparison of the two groups of samples is plotted according to the standardized expression mean. GO and KEGG pathway enrichment analysis were performed with ClusterProfiler R package (v3.18.1) based on the enriched peak and differentially enriched region-associated genes. ATAC-seq was performed in duplicate for each condition, and each replicate was independently processed and analyzed.</p></sec><sec id="s4-7"><title>BioID proximity ligation and mass spectrometry analysis</title><p>The expression vectors <italic>pGIPZ-nlsGFP</italic>, <italic>pGIPZ-nlsYAP<sup>5SA</sup></italic>, <italic>pGIPZ-nlsTAZ<sup>4SA</sup></italic>, <italic>pGIPZ-VGLL2-NCOA2</italic>, and <italic>pGIPZ-TEAD1-NCOA2</italic> generated by PCR sub-cloning into the <italic>pGIPZ</italic> vector were transiently transfected into HEK293T cells. The biotin treatment and BioID pull-down procedures were performed as described previously (<xref ref-type="bibr" rid="bib41">Roux et al., 2012</xref>). Briefly, 24 hours after transfection, the cells at ~80% confluence were treated with biotin at 50 μM for 24 hours. After washing with cold PBS, the cells were lysed in lysis buffer (50 mM Tris–HCl, pH 7.5, 150 mM NaCl, 1% NP-40, 1 mM EDTA, 1 mM EGTA, 0.1% SDS, 0.5% sodium deoxycholate, 250 U of benzonase, and protease inhibitor), and the cell lysate was incubated at 4°C for 1 hour and sonicated on ice three times. The supernatant was then mixed with pre-washed streptavidin Sepharose beads (cat. 17511301, GE Healthcare, Bronx, NY, USA) and incubated at 4°C with rotation for 3 hours. After affinity purification, the agarose beads were washed with lysis buffer followed by two washes with TAP buffer (50 mM HEPES-KOH, pH 8.0, 100 mM KCl, 10% glycerol, 2 mM EDTA, and 0.1% NP-40) and three washes with ABC buffer (50 mM ammonium bicarbonate, pH 8.0). Protein samples were then eluted by boiling for 5 minutes at 95°C in SDS-containing buffer and collected from SDS-PAGE gels before subjecting to mass spectrometry analysis. MS data were searched against a protein database (UniProt KB) using the Mascot search engine program (Matrix Science, London, UK) for protein identification. MS data were validated using the Scaffold 4 program (Proteome Software Inc, Portland OR, USA).</p></sec><sec id="s4-8"><title>Soft agar colony formation and EdU-based proliferation assays</title><p>The soft agar colony formation protocol was described in <xref ref-type="bibr" rid="bib6">Borowicz et al., 2014</xref>. Briefly, in a well of a 6-well plate, a bottom layer of 1% agar in growth media (DMEM + 10% FBS) was plated and solidified, followed by a top layer of 0.6% agar + growth media containing 5000 C2C12 cells with or without expressing VGLL2-NCOA2 or TEAD1-NCOA2. A485 (cat. S8740, SelleckChem, Houston, TX, USA) was dissolved in DMSO to prepare 5 mM stock solution. 1 ml of growth media with or without A485 (5 μM working concentration) was added to the top of each well and replenished every 2–3 days. Colony growth was monitored under a microscope for 2 weeks. Colonies from each group were imaged using a Zeiss Axio Photo Observer microscope. Eight colonies from each group were randomly selected for size measurement, and the diameter of each colony was measured using ZEN 3.2 blue edition software. Colony numbers were counted from three random fields of view and representative images were shown.</p><p>Cell proliferation was assessed using the BeyoClick EdU Cell Proliferation Kit with Alexa Fluor 488 (Beyotime, C0071) according to the manufacturer’s protocol. Briefly, cells were incubated with 10 μM EdU for 120 minutes, followed by digestion with 0.25% trypsin-EDTA. The cells were then fixed in 4% paraformaldehyde (PFA) and permeabilized with PBS containing 0.3% Triton X-100 at room temperature for 15 minutes. After three washes with PBS containing 3% BSA, a click reaction solution was added and incubated at room temperature for 30 minutes, followed by Hoechst 33342 counterstaining. EdU detection assays were performed in triplicate, and representative images were shown.</p></sec><sec id="s4-9"><title>Mouse allograft experiments and tumor processing</title><p>All animal protocols and procedures were approved by the institutional animal care and use committees at the Shanghai Chest Hospital and the University of Massachusetts Chan Medical School. Nude mice were purchased from The Jackson Laboratory (male, 3–4 weeks, NU/J, cat. 002019, Shanghai, China). Nude mice were randomly divided into groups. C2C12-control, C2C12-VGLL2-NCOA2, and C2C12-TEAD1-NCOA2 cell lines were utilized in allograft experiments adapted from <xref ref-type="bibr" rid="bib57">Watson et al., 2023</xref>. Five million cells were resuspended in 100 μl of sterile PBS and injected intramuscularly into the leg of nude mice under anesthesia. Each experimental group had six mice, and mouse legs were assessed 5 days after initial injection. Based on the weight of each mouse, an appropriate volume of the A485 stock solution (5 mM in DMSO) was diluted in 500 μl saline and then administered daily via intraperitoneal injection at a dose of 100 mg/kg (<xref ref-type="bibr" rid="bib29">Lasko et al., 2017</xref>). The height and width of the injected legs were measured using calipers to calculate the volume until 30 days post-injection (initial leg volume was 50–80 mm<sup>3</sup>). Tumor tissue was snap-frozen in liquid nitrogen, and RNA was isolated with Trizol for qPCR analysis. For immunohistochemistry (IHC), tumors were fixed in a 4% PFA solution and mounted in paraffin blocks for microtomy.</p></sec><sec id="s4-10"><title>Immunohistochemistry</title><p>Sections were deparaffinized and rehydrated before undergoing heat-induced antigen retrieval in 10 mM sodium citrate buffer (pH 6.0, Solarbio, cat. C1013) for 30 minutes. Slides were blocked for endogenous peroxidase for 20 minutes, then blocked for 1 hour in 5% BSA, 1% goat serum, 0.1% Tween-20 buffer in PBS, and incubated overnight at 4°C with the primary antibody diluted in blocking buffer or SignalStain Antibody Diluent (cat. 8112, Cell Signaling Technology). Slides were incubated with biotinylated secondary antibodies for 1 hour at room temperature, and the signal was detected using the Vectastain Elite ABC kit (cat. PK-6105, Vector Laboratories, Newark, CA, USA). Hematoxylin was used for counterstaining in IHC. Antibodies and dilutions used in the studies: Ki67 (cat. 12202, 1:500, Cell Signaling Technology) and Desmin (cat. 5332, 1:100, Cell Signaling Technology).</p></sec><sec id="s4-11"><title>Statistics and reproducibility</title><p>Statistical analyses were performed using GraphPad Prism 8 software or R. The repetition of the experiment is shown in the figures and corresponding figure legends. The results were expressed as the mean ± SEM. Statistical significance was determined using a one-way ANOVA for most datasets. Student’s <italic>t</italic>-test was used when comparing two groups.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Validation, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Data curation, Validation, Visualization, Methodology</p></fn><fn fn-type="con" id="con3"><p>Validation</p></fn><fn fn-type="con" id="con4"><p>Validation</p></fn><fn fn-type="con" id="con5"><p>Validation</p></fn><fn fn-type="con" id="con6"><p>Validation</p></fn><fn fn-type="con" id="con7"><p>Validation</p></fn><fn fn-type="con" id="con8"><p>Validation</p></fn><fn fn-type="con" id="con9"><p>Validation</p></fn><fn fn-type="con" id="con10"><p>Funding acquisition</p></fn><fn fn-type="con" id="con11"><p>Data curation, Funding acquisition</p></fn><fn fn-type="con" id="con12"><p>Investigation, Data curation, Supervision, Funding acquisition, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con13"><p>Investigation, Data curation, Supervision, Funding acquisition, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>All animal protocols and procedures were approved by the animal ethics committee at the Shanghai Chest Hospital (reference numbers: KS(Y)24388).</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>RNA-seq analysis showing the genes whose expression was significantly changed in HEK293T cells expressing VGLL2-NCOA2, p-value &lt;0.05, Log2 Fold Change &gt;1 or Log2 Fold Change &lt; –1.</title></caption><media xlink:href="elife-98386-supp1-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>RNA-seq analysis showing the genes whose expression was significantly changed in HEK293T cells expressing TEAD1-NCOA2, p-value &lt;0.05, Log2 Fold Change &gt;1 or Log2 Fold Change &lt; –1.</title></caption><media xlink:href="elife-98386-supp2-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>RNA-seq analysis showing the genes whose expression was significantly changed in HEK293T cells expressing YAP5SA, p-value &lt;0.05, Log2 Fold Change &gt;1 or Log2 Fold Change &lt; –1.</title></caption><media xlink:href="elife-98386-supp3-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp4"><label>Supplementary file 4.</label><caption><title>List of specific BioID hits obtained with BirA*-YAP<sup>5SA</sup>, BirA*-TAZ<sup>4SA</sup>, BirA*-VGLL2-NCOA2, and BirA*-TEAD1-NCOA2.</title></caption><media mimetype="application" mime-subtype="xls" xlink:href="elife-98386-supp4-v1.xls"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-98386-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>Sequencing data have been deposited in Gene Expression Omnibus (GEO) under accession codes GSE260781, GSE260782, and GSE260783.</p><p>The following datasets were generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>J</given-names></name><name><surname>Guo</surname><given-names>S</given-names></name><name><surname>Hu X</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="2024">2024</year><data-title>Effect of VGLL2-NCOA2, YAP5SA and GFP overexpression on chromatin accessibility profiling in HEK293T cells (ATAC-Seq)</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE260781">GSE260781</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset2"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>J</given-names></name><name><surname>Guo</surname><given-names>S</given-names></name><name><surname>Hu X</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="2024">2024</year><data-title>VGLL2-NCOA2 and TEAD1-NCOA2 fusions recruited p300 to drive TEAD-dependent transcription (CUT&amp;RUN)</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE260782">GSE260782</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset3"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>J</given-names></name><name><surname>Guo</surname><given-names>S</given-names></name><name><surname>Hu X</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="2024">2024</year><data-title>Effect of VGLL2-NCOA2, TEAD1-NCOA2 and YAP5SA overexpression on mRNA expression in HEK293T cells (RNA-Seq)</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE260783">GSE260783</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>This work was supported by grants from the National Institutes of Health (R01DK127207 and R01DK127180 to JM, R01CA238270 to XW and JM) and the National Natural Science Foundation of China (82173015 to JW). We also thank the members of the Wang lab and Mao lab for their helpful discussions.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alaggio</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Sung</surname><given-names>YS</given-names></name><name><surname>Huang</surname><given-names>SC</given-names></name><name><surname>Chen</surname><given-names>CL</given-names></name><name><surname>Bisogno</surname><given-names>G</given-names></name><name><surname>Zin</surname><given-names>A</given-names></name><name><surname>Agaram</surname><given-names>NP</given-names></name><name><surname>LaQuaglia</surname><given-names>MP</given-names></name><name><surname>Wexler</surname><given-names>LH</given-names></name><name><surname>Antonescu</surname><given-names>CR</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A molecular study of pediatric spindle and sclerosing rhabdomyosarcoma: identification of novel and recurrent vgll2-related fusions in infantile cases</article-title><source>The American Journal of Surgical Pathology</source><volume>40</volume><fpage>224</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1097/PAS.0000000000000538</pub-id><pub-id pub-id-type="pmid">26501226</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bajic</surname><given-names>M</given-names></name><name><surname>Maher</surname><given-names>KA</given-names></name><name><surname>Deal</surname><given-names>RB</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Identification of open chromatin regions in plant genomes using atac-seq</article-title><source>Methods in Molecular Biology</source><volume>1675</volume><fpage>183</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-7318-7_12</pub-id><pub-id pub-id-type="pmid">29052193</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bamforth</surname><given-names>SD</given-names></name><name><surname>Bragança</surname><given-names>J</given-names></name><name><surname>Eloranta</surname><given-names>JJ</given-names></name><name><surname>Murdoch</surname><given-names>JN</given-names></name><name><surname>Marques</surname><given-names>FI</given-names></name><name><surname>Kranc</surname><given-names>KR</given-names></name><name><surname>Farza</surname><given-names>H</given-names></name><name><surname>Henderson</surname><given-names>DJ</given-names></name><name><surname>Hurst</surname><given-names>HC</given-names></name><name><surname>Bhattacharya</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Cardiac malformations, adrenal agenesis, neural crest defects and exencephaly in mice lacking Cited2, a new Tfap2 co-activator</article-title><source>Nature Genetics</source><volume>29</volume><fpage>469</fpage><lpage>474</lpage><pub-id pub-id-type="doi">10.1038/ng768</pub-id><pub-id pub-id-type="pmid">11694877</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bannister</surname><given-names>AJ</given-names></name><name><surname>Kouzarides</surname><given-names>T</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>The CBP co-activator is a histone acetyltransferase</article-title><source>Nature</source><volume>384</volume><fpage>641</fpage><lpage>643</lpage><pub-id pub-id-type="doi">10.1038/384641a0</pub-id><pub-id pub-id-type="pmid">8967953</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhattacharya</surname><given-names>S</given-names></name><name><surname>Michels</surname><given-names>CL</given-names></name><name><surname>Leung</surname><given-names>MK</given-names></name><name><surname>Arany</surname><given-names>ZP</given-names></name><name><surname>Kung</surname><given-names>AL</given-names></name><name><surname>Livingston</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Functional role of p35srj, a novel P300/CBP binding protein, during transactivation by HIF-1</article-title><source>Genes &amp; Development</source><volume>13</volume><fpage>64</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1101/gad.13.1.64</pub-id><pub-id pub-id-type="pmid">9887100</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borowicz</surname><given-names>S</given-names></name><name><surname>Van Scoyk</surname><given-names>M</given-names></name><name><surname>Avasarala</surname><given-names>S</given-names></name><name><surname>Karuppusamy Rathinam</surname><given-names>MK</given-names></name><name><surname>Tauler</surname><given-names>J</given-names></name><name><surname>Bikkavilli</surname><given-names>RK</given-names></name><name><surname>Winn</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The soft agar colony formation assay</article-title><source>Journal of Visualized Experiments</source><volume>PMID</volume><elocation-id>e51998</elocation-id><pub-id pub-id-type="doi">10.3791/51998</pub-id><pub-id pub-id-type="pmid">25408172</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buenrostro</surname><given-names>JD</given-names></name><name><surname>Giresi</surname><given-names>PG</given-names></name><name><surname>Zaba</surname><given-names>LC</given-names></name><name><surname>Chang</surname><given-names>HY</given-names></name><name><surname>Greenleaf</surname><given-names>WJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position</article-title><source>Nature Methods</source><volume>10</volume><fpage>1213</fpage><lpage>1218</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2688</pub-id><pub-id pub-id-type="pmid">24097267</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>J</given-names></name><name><surname>Choi</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Pulgar Prieto</surname><given-names>KD</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Pan</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>YAP-VGLL4 antagonism defines the major physiological function of the Hippo signaling effector YAP</article-title><source>Genes &amp; Development</source><volume>36</volume><fpage>1119</fpage><lpage>1128</lpage><pub-id pub-id-type="doi">10.1101/gad.350127.122</pub-id><pub-id pub-id-type="pmid">36522128</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calses</surname><given-names>PC</given-names></name><name><surname>Crawford</surname><given-names>JJ</given-names></name><name><surname>Lill</surname><given-names>JR</given-names></name><name><surname>Dey</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Hippo pathway in cancer: aberrant regulation and therapeutic opportunities</article-title><source>Trends in Cancer</source><volume>5</volume><fpage>297</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.1016/j.trecan.2019.04.001</pub-id><pub-id pub-id-type="pmid">31174842</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>P</given-names></name><name><surname>Han</surname><given-names>X</given-names></name><name><surname>Zheng</surname><given-names>B</given-names></name><name><surname>DeRan</surname><given-names>M</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Jarugumilli</surname><given-names>GK</given-names></name><name><surname>Deng</surname><given-names>H</given-names></name><name><surname>Pan</surname><given-names>D</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Autopalmitoylation of TEAD proteins regulates transcriptional output of the Hippo pathway</article-title><source>Nature Chemical Biology</source><volume>12</volume><fpage>282</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.1038/nchembio.2036</pub-id><pub-id pub-id-type="pmid">26900866</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Rudzinski</surname><given-names>ER</given-names></name><name><surname>Arnold</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Challenges in the diagnosis of pediatric spindle cell/sclerosing rhabdomyosarcoma</article-title><source>Surgical Pathology Clinics</source><volume>13</volume><fpage>729</fpage><lpage>738</lpage><pub-id pub-id-type="doi">10.1016/j.path.2020.08.010</pub-id><pub-id pub-id-type="pmid">33183730</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chrivia</surname><given-names>JC</given-names></name><name><surname>Kwok</surname><given-names>RP</given-names></name><name><surname>Lamb</surname><given-names>N</given-names></name><name><surname>Hagiwara</surname><given-names>M</given-names></name><name><surname>Montminy</surname><given-names>MR</given-names></name><name><surname>Goodman</surname><given-names>RH</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Phosphorylated CREB binds specifically to the nuclear protein CBP</article-title><source>Nature</source><volume>365</volume><fpage>855</fpage><lpage>859</lpage><pub-id pub-id-type="doi">10.1038/365855a0</pub-id><pub-id pub-id-type="pmid">8413673</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cotton</surname><given-names>JL</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Park</surname><given-names>JS</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Ou</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>LJ</given-names></name><name><surname>Ip</surname><given-names>YT</given-names></name><name><surname>Johnson</surname><given-names>RL</given-names></name><name><surname>Mao</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>YAP/TAZ and Hedgehog coordinate growth and patterning in gastrointestinal mesenchyme</article-title><source>Developmental Cell</source><volume>43</volume><fpage>35</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2017.08.019</pub-id><pub-id pub-id-type="pmid">28943241</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cyrta</surname><given-names>J</given-names></name><name><surname>Gauthier</surname><given-names>A</given-names></name><name><surname>Karanian</surname><given-names>M</given-names></name><name><surname>Vieira</surname><given-names>AF</given-names></name><name><surname>Cardoen</surname><given-names>L</given-names></name><name><surname>Jehanno</surname><given-names>N</given-names></name><name><surname>Bouvet</surname><given-names>M</given-names></name><name><surname>Bouvier</surname><given-names>C</given-names></name><name><surname>Komuta</surname><given-names>M</given-names></name><name><surname>Le Loarer</surname><given-names>F</given-names></name><name><surname>Orbach</surname><given-names>D</given-names></name><name><surname>Rome</surname><given-names>A</given-names></name><name><surname>Minard-Colin</surname><given-names>V</given-names></name><name><surname>Brichard</surname><given-names>B</given-names></name><name><surname>Pluchart</surname><given-names>C</given-names></name><name><surname>Thebaud</surname><given-names>E</given-names></name><name><surname>Renard</surname><given-names>M</given-names></name><name><surname>Pannier</surname><given-names>S</given-names></name><name><surname>Brisse</surname><given-names>H</given-names></name><name><surname>Petit</surname><given-names>P</given-names></name><name><surname>Benoist</surname><given-names>C</given-names></name><name><surname>Schleiermacher</surname><given-names>G</given-names></name><name><surname>Geoerger</surname><given-names>B</given-names></name><name><surname>Vincent-Salomon</surname><given-names>A</given-names></name><name><surname>Fréneaux</surname><given-names>P</given-names></name><name><surname>Pierron</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Infantile rhabdomyosarcomas with vgll2 rearrangement are not always an indolent disease: a study of 4 aggressive cases with clinical, pathologic, molecular, and radiologic findings</article-title><source>The American Journal of Surgical Pathology</source><volume>45</volume><fpage>854</fpage><lpage>867</lpage><pub-id pub-id-type="doi">10.1097/PAS.0000000000001702</pub-id><pub-id pub-id-type="pmid">33949344</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Driskill</surname><given-names>JH</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>BK</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Cai</surname><given-names>J</given-names></name><name><surname>Rakheja</surname><given-names>D</given-names></name><name><surname>Dellinger</surname><given-names>M</given-names></name><name><surname>Pan</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>WWTR1(TAZ)-CAMTA1 reprograms endothelial cells to drive epithelioid hemangioendothelioma</article-title><source>Genes &amp; Development</source><volume>35</volume><fpage>495</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1101/gad.348221.120</pub-id><pub-id pub-id-type="pmid">33766984</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dupont</surname><given-names>S</given-names></name><name><surname>Morsut</surname><given-names>L</given-names></name><name><surname>Aragona</surname><given-names>M</given-names></name><name><surname>Enzo</surname><given-names>E</given-names></name><name><surname>Giulitti</surname><given-names>S</given-names></name><name><surname>Cordenonsi</surname><given-names>M</given-names></name><name><surname>Zanconato</surname><given-names>F</given-names></name><name><surname>Le Digabel</surname><given-names>J</given-names></name><name><surname>Forcato</surname><given-names>M</given-names></name><name><surname>Bicciato</surname><given-names>S</given-names></name><name><surname>Elvassore</surname><given-names>N</given-names></name><name><surname>Piccolo</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Role of YAP/TAZ in mechanotransduction</article-title><source>Nature</source><volume>474</volume><fpage>179</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1038/nature10137</pub-id><pub-id pub-id-type="pmid">21654799</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faucheux</surname><given-names>C</given-names></name><name><surname>Naye</surname><given-names>F</given-names></name><name><surname>Tréguer</surname><given-names>K</given-names></name><name><surname>Fédou</surname><given-names>S</given-names></name><name><surname>Thiébaud</surname><given-names>P</given-names></name><name><surname>Théze</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Vestigial like gene family expression in <italic>Xenopus</italic>: common and divergent features with other vertebrates</article-title><source>The International Journal of Developmental Biology</source><volume>54</volume><fpage>1375</fpage><lpage>1382</lpage><pub-id pub-id-type="doi">10.1387/ijdb.103080cf</pub-id><pub-id pub-id-type="pmid">20712000</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franklin</surname><given-names>JM</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Guan</surname><given-names>KL</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Insights into recent findings and clinical application of YAP and TAZ in cancer</article-title><source>Nature Reviews. Cancer</source><volume>23</volume><fpage>512</fpage><lpage>525</lpage><pub-id pub-id-type="doi">10.1038/s41568-023-00579-1</pub-id><pub-id pub-id-type="pmid">37308716</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia</surname><given-names>K</given-names></name><name><surname>Gingras</surname><given-names>AC</given-names></name><name><surname>Harvey</surname><given-names>KF</given-names></name><name><surname>Tanas</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>TAZ/YAP fusion proteins: mechanistic insights and therapeutic opportunities</article-title><source>Trends in Cancer</source><volume>8</volume><fpage>1033</fpage><lpage>1045</lpage><pub-id pub-id-type="doi">10.1016/j.trecan.2022.08.002</pub-id><pub-id pub-id-type="pmid">36096997</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goebel</surname><given-names>EA</given-names></name><name><surname>Hernandez Bonilla</surname><given-names>S</given-names></name><name><surname>Dong</surname><given-names>F</given-names></name><name><surname>Dickson</surname><given-names>BC</given-names></name><name><surname>Hoang</surname><given-names>LN</given-names></name><name><surname>Hardisson</surname><given-names>D</given-names></name><name><surname>Lacambra</surname><given-names>MD</given-names></name><name><surname>Lu</surname><given-names>FI</given-names></name><name><surname>Fletcher</surname><given-names>CDM</given-names></name><name><surname>Crum</surname><given-names>CP</given-names></name><name><surname>Antonescu</surname><given-names>CR</given-names></name><name><surname>Nucci</surname><given-names>MR</given-names></name><name><surname>Kolin</surname><given-names>DL</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Uterine Tumor Resembling Ovarian Sex Cord Tumor (UTROSCT): a morphologic and molecular study of 26 cases confirms recurrent NCOA1-3 rearrangement</article-title><source>The American Journal of Surgical Pathology</source><volume>44</volume><fpage>30</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1097/PAS.0000000000001348</pub-id><pub-id pub-id-type="pmid">31464709</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hogg</surname><given-names>SJ</given-names></name><name><surname>Motorna</surname><given-names>O</given-names></name><name><surname>Cluse</surname><given-names>LA</given-names></name><name><surname>Johanson</surname><given-names>TM</given-names></name><name><surname>Coughlan</surname><given-names>HD</given-names></name><name><surname>Raviram</surname><given-names>R</given-names></name><name><surname>Myers</surname><given-names>RM</given-names></name><name><surname>Costacurta</surname><given-names>M</given-names></name><name><surname>Todorovski</surname><given-names>I</given-names></name><name><surname>Pijpers</surname><given-names>L</given-names></name><name><surname>Bjelosevic</surname><given-names>S</given-names></name><name><surname>Williams</surname><given-names>T</given-names></name><name><surname>Huskins</surname><given-names>SN</given-names></name><name><surname>Kearney</surname><given-names>CJ</given-names></name><name><surname>Devlin</surname><given-names>JR</given-names></name><name><surname>Fan</surname><given-names>Z</given-names></name><name><surname>Jabbari</surname><given-names>JS</given-names></name><name><surname>Martin</surname><given-names>BP</given-names></name><name><surname>Fareh</surname><given-names>M</given-names></name><name><surname>Kelly</surname><given-names>MJ</given-names></name><name><surname>Dupéré-Richer</surname><given-names>D</given-names></name><name><surname>Sandow</surname><given-names>JJ</given-names></name><name><surname>Feran</surname><given-names>B</given-names></name><name><surname>Knight</surname><given-names>D</given-names></name><name><surname>Khong</surname><given-names>T</given-names></name><name><surname>Spencer</surname><given-names>A</given-names></name><name><surname>Harrison</surname><given-names>SJ</given-names></name><name><surname>Gregory</surname><given-names>G</given-names></name><name><surname>Wickramasinghe</surname><given-names>VO</given-names></name><name><surname>Webb</surname><given-names>AI</given-names></name><name><surname>Taberlay</surname><given-names>PC</given-names></name><name><surname>Bromberg</surname><given-names>KD</given-names></name><name><surname>Lai</surname><given-names>A</given-names></name><name><surname>Papenfuss</surname><given-names>AT</given-names></name><name><surname>Smyth</surname><given-names>GK</given-names></name><name><surname>Allan</surname><given-names>RS</given-names></name><name><surname>Licht</surname><given-names>JD</given-names></name><name><surname>Landau</surname><given-names>DA</given-names></name><name><surname>Abdel-Wahab</surname><given-names>O</given-names></name><name><surname>Shortt</surname><given-names>J</given-names></name><name><surname>Vervoort</surname><given-names>SJ</given-names></name><name><surname>Johnstone</surname><given-names>RW</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition</article-title><source>Molecular Cell</source><volume>81</volume><fpage>2183</fpage><lpage>2200</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2021.04.015</pub-id><pub-id pub-id-type="pmid">34019788</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holden</surname><given-names>JK</given-names></name><name><surname>Crawford</surname><given-names>JJ</given-names></name><name><surname>Noland</surname><given-names>CL</given-names></name><name><surname>Schmidt</surname><given-names>S</given-names></name><name><surname>Zbieg</surname><given-names>JR</given-names></name><name><surname>Lacap</surname><given-names>JA</given-names></name><name><surname>Zang</surname><given-names>R</given-names></name><name><surname>Miller</surname><given-names>GM</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Beroza</surname><given-names>P</given-names></name><name><surname>Reja</surname><given-names>R</given-names></name><name><surname>Lee</surname><given-names>W</given-names></name><name><surname>Tom</surname><given-names>JYK</given-names></name><name><surname>Fong</surname><given-names>R</given-names></name><name><surname>Steffek</surname><given-names>M</given-names></name><name><surname>Clausen</surname><given-names>S</given-names></name><name><surname>Hagenbeek</surname><given-names>TJ</given-names></name><name><surname>Hu</surname><given-names>T</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Shen</surname><given-names>HC</given-names></name><name><surname>Cunningham</surname><given-names>CN</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Small molecule dysregulation of TEAD lipidation induces a dominant-negative inhibition of hippo pathway signaling</article-title><source>Cell Reports</source><volume>31</volume><elocation-id>107809</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2020.107809</pub-id><pub-id pub-id-type="pmid">32579935</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Erb</surname><given-names>H</given-names></name><name><surname>Singh</surname><given-names>A</given-names></name><name><surname>Mao</surname><given-names>J</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Discovery of a new class of reversible TEA domain transcription factor inhibitors with a novel binding mode</article-title><source>eLife</source><volume>11</volume><elocation-id>e80210</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.80210</pub-id><pub-id pub-id-type="pmid">36398861</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Möller</surname><given-names>E</given-names></name><name><surname>Nord</surname><given-names>KH</given-names></name><name><surname>Mandahl</surname><given-names>N</given-names></name><name><surname>Steyern</surname><given-names>FV</given-names></name><name><surname>Domanski</surname><given-names>HA</given-names></name><name><surname>Mariño-Enríquez</surname><given-names>A</given-names></name><name><surname>Magnusson</surname><given-names>L</given-names></name><name><surname>Nilsson</surname><given-names>J</given-names></name><name><surname>Sciot</surname><given-names>R</given-names></name><name><surname>Fletcher</surname><given-names>CD</given-names></name><name><surname>Debiec-Rychter</surname><given-names>M</given-names></name><name><surname>Mertens</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Fusion of the AHRR and NCOA2 genes through a recurrent translocation t(5;8)(p15;q13) in soft tissue angiofibroma results in upregulation of aryl hydrocarbon receptor target genes</article-title><source>Genes Chromosomes Cancer</source><volume>51</volume><fpage>510</fpage><lpage>520</lpage><pub-id pub-id-type="doi">10.1002/gcc.21939</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaneda</surname><given-names>A</given-names></name><name><surname>Seike</surname><given-names>T</given-names></name><name><surname>Danjo</surname><given-names>T</given-names></name><name><surname>Nakajima</surname><given-names>T</given-names></name><name><surname>Otsubo</surname><given-names>N</given-names></name><name><surname>Yamaguchi</surname><given-names>D</given-names></name><name><surname>Tsuji</surname><given-names>Y</given-names></name><name><surname>Hamaguchi</surname><given-names>K</given-names></name><name><surname>Yasunaga</surname><given-names>M</given-names></name><name><surname>Nishiya</surname><given-names>Y</given-names></name><name><surname>Suzuki</surname><given-names>M</given-names></name><name><surname>Saito</surname><given-names>JI</given-names></name><name><surname>Yatsunami</surname><given-names>R</given-names></name><name><surname>Nakamura</surname><given-names>S</given-names></name><name><surname>Sekido</surname><given-names>Y</given-names></name><name><surname>Mori</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The novel potent TEAD inhibitor, K-975, inhibits YAP1/TAZ-TEAD protein-protein interactions and exerts an anti-tumor effect on malignant pleural mesothelioma</article-title><source>American Journal of Cancer Research</source><volume>10</volume><fpage>4399</fpage><lpage>4415</lpage><pub-id pub-id-type="pmid">33415007</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>DI</given-names></name><name><surname>Roux</surname><given-names>KJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Filling the void: proximity-based labeling of proteins in living cells</article-title><source>Trends in Cell Biology</source><volume>26</volume><fpage>804</fpage><lpage>817</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2016.09.004</pub-id><pub-id pub-id-type="pmid">27667171</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koontz</surname><given-names>LM</given-names></name><name><surname>Liu-Chittenden</surname><given-names>Y</given-names></name><name><surname>Yin</surname><given-names>F</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Pan</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The hippo effector yorkie controls normal tissue growth by antagonizing scalloped-mediated default repression</article-title><source>Developmental Cell</source><volume>25</volume><fpage>388</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2013.04.021</pub-id><pub-id pub-id-type="pmid">23725764</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kulkarni</surname><given-names>A</given-names></name><name><surname>Chang</surname><given-names>MT</given-names></name><name><surname>Vissers</surname><given-names>JHA</given-names></name><name><surname>Dey</surname><given-names>A</given-names></name><name><surname>Harvey</surname><given-names>KF</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The hippo pathway as a driver of select human cancers</article-title><source>Trends in Cancer</source><volume>6</volume><fpage>781</fpage><lpage>796</lpage><pub-id pub-id-type="doi">10.1016/j.trecan.2020.04.004</pub-id><pub-id pub-id-type="pmid">32446746</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lasko</surname><given-names>LM</given-names></name><name><surname>Jakob</surname><given-names>CG</given-names></name><name><surname>Edalji</surname><given-names>RP</given-names></name><name><surname>Qiu</surname><given-names>W</given-names></name><name><surname>Montgomery</surname><given-names>D</given-names></name><name><surname>Digiammarino</surname><given-names>EL</given-names></name><name><surname>Hansen</surname><given-names>TM</given-names></name><name><surname>Risi</surname><given-names>RM</given-names></name><name><surname>Frey</surname><given-names>R</given-names></name><name><surname>Manaves</surname><given-names>V</given-names></name><name><surname>Shaw</surname><given-names>B</given-names></name><name><surname>Algire</surname><given-names>M</given-names></name><name><surname>Hessler</surname><given-names>P</given-names></name><name><surname>Lam</surname><given-names>LT</given-names></name><name><surname>Uziel</surname><given-names>T</given-names></name><name><surname>Faivre</surname><given-names>E</given-names></name><name><surname>Ferguson</surname><given-names>D</given-names></name><name><surname>Buchanan</surname><given-names>FG</given-names></name><name><surname>Martin</surname><given-names>RL</given-names></name><name><surname>Torrent</surname><given-names>M</given-names></name><name><surname>Chiang</surname><given-names>GG</given-names></name><name><surname>Karukurichi</surname><given-names>K</given-names></name><name><surname>Langston</surname><given-names>JW</given-names></name><name><surname>Weinert</surname><given-names>BT</given-names></name><name><surname>Choudhary</surname><given-names>C</given-names></name><name><surname>de Vries</surname><given-names>P</given-names></name><name><surname>Van Drie</surname><given-names>JH</given-names></name><name><surname>McElligott</surname><given-names>D</given-names></name><name><surname>Kesicki</surname><given-names>E</given-names></name><name><surname>Marmorstein</surname><given-names>R</given-names></name><name><surname>Sun</surname><given-names>C</given-names></name><name><surname>Cole</surname><given-names>PA</given-names></name><name><surname>Rosenberg</surname><given-names>SH</given-names></name><name><surname>Michaelides</surname><given-names>MR</given-names></name><name><surname>Lai</surname><given-names>A</given-names></name><name><surname>Bromberg</surname><given-names>KD</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Discovery of a selective catalytic P300/CBP inhibitor that targets lineage-specific tumours</article-title><source>Nature</source><volume>550</volume><fpage>128</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1038/nature24028</pub-id><pub-id pub-id-type="pmid">28953875</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Jarugumilli</surname><given-names>GK</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Dang</surname><given-names>K</given-names></name><name><surname>Cotton</surname><given-names>JL</given-names></name><name><surname>Xiol</surname><given-names>J</given-names></name><name><surname>Chan</surname><given-names>PY</given-names></name><name><surname>DeRan</surname><given-names>M</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Zhu</surname><given-names>LJ</given-names></name><name><surname>Li</surname><given-names>JH</given-names></name><name><surname>Leiter</surname><given-names>AB</given-names></name><name><surname>Ip</surname><given-names>YT</given-names></name><name><surname>Camargo</surname><given-names>FD</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name><name><surname>Johnson</surname><given-names>RL</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Mao</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Lats1/2 sustain intestinal stem cells and wnt activation through TEAD-dependent and independent transcription</article-title><source>Cell Stem Cell</source><volume>26</volume><fpage>675</fpage><lpage>692</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2020.03.002</pub-id><pub-id pub-id-type="pmid">32259481</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Negi</surname><given-names>V</given-names></name><name><surname>Yang</surname><given-names>P</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Jagannathan</surname><given-names>R</given-names></name><name><surname>Moulik</surname><given-names>M</given-names></name><name><surname>Yechoor</surname><given-names>VK</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>VGLL4 and MENIN function as TEAD1 corepressors to block pancreatic β cell proliferation</article-title><source>Cell Reports</source><volume>42</volume><elocation-id>111904</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2022.111904</pub-id><pub-id pub-id-type="pmid">36662616</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Rajurkar</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Cotton</surname><given-names>JL</given-names></name><name><surname>Ou</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>LJ</given-names></name><name><surname>Goel</surname><given-names>HL</given-names></name><name><surname>Mercurio</surname><given-names>AM</given-names></name><name><surname>Park</surname><given-names>JS</given-names></name><name><surname>Davis</surname><given-names>RJ</given-names></name><name><surname>Mao</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Tead and AP1 coordinate transcription and motility</article-title><source>Cell Reports</source><volume>14</volume><fpage>1169</fpage><lpage>1180</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2015.12.104</pub-id><pub-id pub-id-type="pmid">26832411</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>B</given-names></name><name><surname>Xia</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>Shao</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>NCOA1/2/3 rearrangements in uterine tumor resembling ovarian sex cord tumor: A clinicopathological and molecular study of 18 cases</article-title><source>Human Pathology</source><volume>135</volume><fpage>65</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1016/j.humpath.2023.01.001</pub-id><pub-id pub-id-type="pmid">36646185</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>S</given-names></name><name><surname>Meng</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Guan</surname><given-names>KL</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The hippo pathway: biology and pathophysiology</article-title><source>Annual Review of Biochemistry</source><volume>88</volume><fpage>577</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.1146/annurev-biochem-013118-111829</pub-id><pub-id pub-id-type="pmid">30566373</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merritt</surname><given-names>N</given-names></name><name><surname>Garcia</surname><given-names>K</given-names></name><name><surname>Rajendran</surname><given-names>D</given-names></name><name><surname>Lin</surname><given-names>ZY</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Mitchell</surname><given-names>KA</given-names></name><name><surname>Borcherding</surname><given-names>N</given-names></name><name><surname>Fullenkamp</surname><given-names>C</given-names></name><name><surname>Chimenti</surname><given-names>MS</given-names></name><name><surname>Gingras</surname><given-names>AC</given-names></name><name><surname>Harvey</surname><given-names>KF</given-names></name><name><surname>Tanas</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>TAZ-CAMTA1 and YAP-TFE3 alter the TAZ/YAP transcriptome by recruiting the ATAC histone acetyltransferase complex</article-title><source>eLife</source><volume>10</volume><elocation-id>e62857</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.62857</pub-id><pub-id pub-id-type="pmid">33913810</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niu</surname><given-names>S</given-names></name><name><surname>Rivera-Colon</surname><given-names>G</given-names></name><name><surname>Lucas</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Aggressive high-grade uterine sarcoma harboring MEIS1-NCOA2 fusion and amplification of multiple 12q13-15 Genes: a case report with morphologic, immunohistochemical, and molecular analysis</article-title><source>International Journal of Gynecological Pathology</source><volume>42</volume><fpage>460</fpage><lpage>465</lpage><pub-id pub-id-type="doi">10.1097/PGP.0000000000000937</pub-id><pub-id pub-id-type="pmid">36811835</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ogryzko</surname><given-names>VV</given-names></name><name><surname>Schiltz</surname><given-names>RL</given-names></name><name><surname>Russanova</surname><given-names>V</given-names></name><name><surname>Howard</surname><given-names>BH</given-names></name><name><surname>Nakatani</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>The transcriptional coactivators P300 and CBP are histone acetyltransferases</article-title><source>Cell</source><volume>87</volume><fpage>953</fpage><lpage>959</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)82001-2</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piccolo</surname><given-names>S</given-names></name><name><surname>Panciera</surname><given-names>T</given-names></name><name><surname>Contessotto</surname><given-names>P</given-names></name><name><surname>Cordenonsi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>YAP/TAZ as master regulators in cancer: modulation, function and therapeutic approaches</article-title><source>Nature Cancer</source><volume>4</volume><fpage>9</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1038/s43018-022-00473-z</pub-id><pub-id pub-id-type="pmid">36564601</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pobbati</surname><given-names>AV</given-names></name><name><surname>Chan</surname><given-names>SW</given-names></name><name><surname>Lee</surname><given-names>I</given-names></name><name><surname>Song</surname><given-names>H</given-names></name><name><surname>Hong</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Structural and functional similarity between the Vgll1-TEAD and the YAP-TEAD complexes</article-title><source>Structure</source><volume>20</volume><fpage>1135</fpage><lpage>1140</lpage><pub-id pub-id-type="doi">10.1016/j.str.2012.04.004</pub-id><pub-id pub-id-type="pmid">22632831</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pobbati</surname><given-names>AV</given-names></name><name><surname>Kumar</surname><given-names>R</given-names></name><name><surname>Rubin</surname><given-names>BP</given-names></name><name><surname>Hong</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Therapeutic targeting of TEAD transcription factors in cancer</article-title><source>Trends in Biochemical Sciences</source><volume>48</volume><fpage>450</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2022.12.005</pub-id><pub-id pub-id-type="pmid">36709077</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roux</surname><given-names>KJ</given-names></name><name><surname>Kim</surname><given-names>DI</given-names></name><name><surname>Raida</surname><given-names>M</given-names></name><name><surname>Burke</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>A promiscuous biotin ligase fusion protein identifies proximal and interacting proteins in mammalian cells</article-title><source>The Journal of Cell Biology</source><volume>196</volume><fpage>801</fpage><lpage>810</lpage><pub-id pub-id-type="doi">10.1083/jcb.201112098</pub-id><pub-id pub-id-type="pmid">22412018</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seavey</surname><given-names>CN</given-names></name><name><surname>Pobbati</surname><given-names>AV</given-names></name><name><surname>Hallett</surname><given-names>A</given-names></name><name><surname>Ma</surname><given-names>S</given-names></name><name><surname>Reynolds</surname><given-names>JP</given-names></name><name><surname>Kanai</surname><given-names>R</given-names></name><name><surname>Lamar</surname><given-names>JM</given-names></name><name><surname>Rubin</surname><given-names>BP</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title><italic>WWTR1</italic>(TAZ)-<italic>CAMTA1</italic> gene fusion is sufficient to dysregulate YAP/TAZ signaling and drive epithelioid hemangioendothelioma tumorigenesis</article-title><source>Genes &amp; Development</source><volume>35</volume><fpage>512</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1101/gad.348220.120</pub-id><pub-id pub-id-type="pmid">33766982</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simon</surname><given-names>E</given-names></name><name><surname>Faucheux</surname><given-names>C</given-names></name><name><surname>Zider</surname><given-names>A</given-names></name><name><surname>Thézé</surname><given-names>N</given-names></name><name><surname>Thiébaud</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>From vestigial to vestigial-like: the <italic>Drosophila</italic> gene that has taken wing</article-title><source>Development Genes and Evolution</source><volume>226</volume><fpage>297</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1007/s00427-016-0546-3</pub-id><pub-id pub-id-type="pmid">27116603</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strehl</surname><given-names>S</given-names></name><name><surname>Nebral</surname><given-names>K</given-names></name><name><surname>König</surname><given-names>M</given-names></name><name><surname>Harbott</surname><given-names>J</given-names></name><name><surname>Strobl</surname><given-names>H</given-names></name><name><surname>Ratei</surname><given-names>R</given-names></name><name><surname>Struski</surname><given-names>S</given-names></name><name><surname>Bielorai</surname><given-names>B</given-names></name><name><surname>Lessard</surname><given-names>M</given-names></name><name><surname>Zimmermann</surname><given-names>M</given-names></name><name><surname>Haas</surname><given-names>OA</given-names></name><name><surname>Izraeli</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>ETV6-NCOA2: A novel fusion gene in acute leukemia associated with coexpression of T-lymphoid and myeloid markers and frequent NOTCH1 mutations</article-title><source>Clinical Cancer Research</source><volume>14</volume><fpage>977</fpage><lpage>983</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-4022</pub-id><pub-id pub-id-type="pmid">18281529</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>L</given-names></name><name><surname>Tao</surname><given-names>Z</given-names></name><name><surname>Jarugumilli</surname><given-names>GK</given-names></name><name><surname>Erb</surname><given-names>H</given-names></name><name><surname>Singh</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Cotton</surname><given-names>JL</given-names></name><name><surname>Greninger</surname><given-names>P</given-names></name><name><surname>Egan</surname><given-names>RK</given-names></name><name><surname>Tony Ip</surname><given-names>Y</given-names></name><name><surname>Benes</surname><given-names>CH</given-names></name><name><surname>Che</surname><given-names>J</given-names></name><name><surname>Mao</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Pharmacological blockade of TEAD-YAP reveals its therapeutic limitation in cancer cells</article-title><source>Nature Communications</source><volume>13</volume><elocation-id>6744</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-022-34559-0</pub-id><pub-id pub-id-type="pmid">36347861</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szulzewsky</surname><given-names>F</given-names></name><name><surname>Holland</surname><given-names>EC</given-names></name><name><surname>Vasioukhin</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>YAP1 and its fusion proteins in cancer initiation, progression and therapeutic resistance</article-title><source>Developmental Biology</source><volume>475</volume><fpage>205</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1016/j.ydbio.2020.12.018</pub-id><pub-id pub-id-type="pmid">33428889</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szulzewsky</surname><given-names>F</given-names></name><name><surname>Arora</surname><given-names>S</given-names></name><name><surname>Arakaki</surname><given-names>AKS</given-names></name><name><surname>Sievers</surname><given-names>P</given-names></name><name><surname>Almiron Bonnin</surname><given-names>DA</given-names></name><name><surname>Paddison</surname><given-names>PJ</given-names></name><name><surname>Sahm</surname><given-names>F</given-names></name><name><surname>Cimino</surname><given-names>PJ</given-names></name><name><surname>Gujral</surname><given-names>TS</given-names></name><name><surname>Holland</surname><given-names>EC</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Both YAP1-MAML2 and constitutively active YAP1 drive the formation of tumors that resemble NF2 mutant meningiomas in mice</article-title><source>Genes &amp; Development</source><volume>36</volume><fpage>857</fpage><lpage>870</lpage><pub-id pub-id-type="doi">10.1101/gad.349876.122</pub-id><pub-id pub-id-type="pmid">36008139</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>GZL</given-names></name><name><surname>Saminathan</surname><given-names>SN</given-names></name><name><surname>Chang</surname><given-names>KTE</given-names></name><name><surname>Odoño</surname><given-names>EG</given-names></name><name><surname>Kuick</surname><given-names>CH</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>VKM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A rare case of congenital spindle cell rhabdomyosarcoma with TEAD1-NCOA2 fusion: a subset of spindle cell rhabdomyosarcoma with indolent behavior</article-title><source>Pathology International</source><volume>70</volume><fpage>234</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1111/pin.12908</pub-id><pub-id pub-id-type="pmid">31999033</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>M</given-names></name><name><surname>Homme</surname><given-names>M</given-names></name><name><surname>Teramura</surname><given-names>Y</given-names></name><name><surname>Kumegawa</surname><given-names>K</given-names></name><name><surname>Yamazaki</surname><given-names>Y</given-names></name><name><surname>Yamashita</surname><given-names>K</given-names></name><name><surname>Osato</surname><given-names>M</given-names></name><name><surname>Maruyama</surname><given-names>R</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>HEY1-NCOA2 expression modulates chondrogenic differentiation and induces mesenchymal chondrosarcoma in mice</article-title><source>JCI Insight</source><volume>8</volume><elocation-id>37212282</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.160279</pub-id><pub-id pub-id-type="pmid">37212282</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>TT</given-names></name><name><surname>Konradi</surname><given-names>AW</given-names></name><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Peng</surname><given-names>X</given-names></name><name><surname>Ma</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>F-X</given-names></name><name><surname>Guan</surname><given-names>K-L</given-names></name><name><surname>Post</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Small molecule inhibitors of TEAD Auto-palmitoylation selectively inhibit proliferation and tumor growth of <italic>NF2</italic>-deficient Mesothelioma</article-title><source>Molecular Cancer Therapeutics</source><volume>20</volume><fpage>986</fpage><lpage>998</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-20-0717</pub-id><pub-id pub-id-type="pmid">33850002</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tauziède-Espariat</surname><given-names>A</given-names></name><name><surname>Siegfried</surname><given-names>A</given-names></name><name><surname>Nicaise</surname><given-names>Y</given-names></name><name><surname>Kergrohen</surname><given-names>T</given-names></name><name><surname>Sievers</surname><given-names>P</given-names></name><name><surname>Vasiljevic</surname><given-names>A</given-names></name><name><surname>Roux</surname><given-names>A</given-names></name><name><surname>Dezamis</surname><given-names>E</given-names></name><name><surname>Benevello</surname><given-names>C</given-names></name><name><surname>Machet</surname><given-names>M-C</given-names></name><name><surname>Michalak</surname><given-names>S</given-names></name><name><surname>Puiseux</surname><given-names>C</given-names></name><name><surname>Llamas-Gutierrez</surname><given-names>F</given-names></name><name><surname>Leblond</surname><given-names>P</given-names></name><name><surname>Bourdeaut</surname><given-names>F</given-names></name><name><surname>Grill</surname><given-names>J</given-names></name><name><surname>Dufour</surname><given-names>C</given-names></name><name><surname>Guerrini-Rousseau</surname><given-names>L</given-names></name><name><surname>Abbou</surname><given-names>S</given-names></name><name><surname>Dangouloff-Ros</surname><given-names>V</given-names></name><name><surname>Boddaert</surname><given-names>N</given-names></name><name><surname>Saffroy</surname><given-names>R</given-names></name><name><surname>Hasty</surname><given-names>L</given-names></name><name><surname>Wahler</surname><given-names>E</given-names></name><name><surname>Pagès</surname><given-names>M</given-names></name><name><surname>Andreiuolo</surname><given-names>F</given-names></name><name><surname>Lechapt</surname><given-names>E</given-names></name><name><surname>Chrétien</surname><given-names>F</given-names></name><name><surname>Blauwblomme</surname><given-names>T</given-names></name><name><surname>Beccaria</surname><given-names>K</given-names></name><name><surname>Pallud</surname><given-names>J</given-names></name><name><surname>Puget</surname><given-names>S</given-names></name><name><surname>Uro-Coste</surname><given-names>E</given-names></name><name><surname>Varlet</surname><given-names>P</given-names></name><collab>RENOCLIP-LOC, the BIOMECA Biomarkers for Ependymomas in Children, Adolescents consortium</collab></person-group><year iso-8601-date="2021">2021</year><article-title>Supratentorial non-RELA, ZFTA-fused ependymomas: a comprehensive phenotype genotype correlation highlighting the number of zinc fingers in ZFTA-NCOA1/2 fusions</article-title><source>Acta Neuropathologica Communications</source><volume>9</volume><elocation-id>135</elocation-id><pub-id pub-id-type="doi">10.1186/s40478-021-01238-y</pub-id><pub-id pub-id-type="pmid">34389065</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>BJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>YAP/TAZ: drivers of tumor growth, metastasis, and resistance to therapy</article-title><source>BioEssays</source><volume>42</volume><elocation-id>e1900162</elocation-id><pub-id pub-id-type="doi">10.1002/bies.201900162</pub-id><pub-id pub-id-type="pmid">32128850</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomomasa</surname><given-names>R</given-names></name><name><surname>Arai</surname><given-names>Y</given-names></name><name><surname>Kawabata-Iwakawa</surname><given-names>R</given-names></name><name><surname>Fukuoka</surname><given-names>K</given-names></name><name><surname>Nakano</surname><given-names>Y</given-names></name><name><surname>Hama</surname><given-names>N</given-names></name><name><surname>Nakata</surname><given-names>S</given-names></name><name><surname>Suzuki</surname><given-names>N</given-names></name><name><surname>Ishi</surname><given-names>Y</given-names></name><name><surname>Tanaka</surname><given-names>S</given-names></name><name><surname>Takahashi</surname><given-names>JA</given-names></name><name><surname>Yuba</surname><given-names>Y</given-names></name><name><surname>Shiota</surname><given-names>M</given-names></name><name><surname>Natsume</surname><given-names>A</given-names></name><name><surname>Kurimoto</surname><given-names>M</given-names></name><name><surname>Shiba</surname><given-names>Y</given-names></name><name><surname>Aoki</surname><given-names>M</given-names></name><name><surname>Nabeshima</surname><given-names>K</given-names></name><name><surname>Enomoto</surname><given-names>T</given-names></name><name><surname>Inoue</surname><given-names>T</given-names></name><name><surname>Fujimura</surname><given-names>J</given-names></name><name><surname>Kondo</surname><given-names>A</given-names></name><name><surname>Yao</surname><given-names>T</given-names></name><name><surname>Okura</surname><given-names>N</given-names></name><name><surname>Hirose</surname><given-names>T</given-names></name><name><surname>Sasaki</surname><given-names>A</given-names></name><name><surname>Nishiyama</surname><given-names>M</given-names></name><name><surname>Ichimura</surname><given-names>K</given-names></name><name><surname>Shibata</surname><given-names>T</given-names></name><name><surname>Hirato</surname><given-names>J</given-names></name><name><surname>Yokoo</surname><given-names>H</given-names></name><name><surname>Nobusawa</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Ependymoma-like tumor with mesenchymal differentiation harboring C11orf95-NCOA1/2 or -RELA fusion: a hitherto unclassified tumor related to ependymoma</article-title><source>Brain Pathology</source><volume>31</volume><elocation-id>e12943</elocation-id><pub-id pub-id-type="doi">10.1111/bpa.12943</pub-id><pub-id pub-id-type="pmid">33576087</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Totaro</surname><given-names>A</given-names></name><name><surname>Panciera</surname><given-names>T</given-names></name><name><surname>Piccolo</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>YAP/TAZ upstream signals and downstream responses</article-title><source>Nature Cell Biology</source><volume>20</volume><fpage>888</fpage><lpage>899</lpage><pub-id pub-id-type="doi">10.1038/s41556-018-0142-z</pub-id><pub-id pub-id-type="pmid">30050119</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waddell</surname><given-names>AR</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Liao</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>CBP/P300: critical co-activators for nuclear steroid hormone receptors and emerging therapeutic targets in prostate and breast cancers</article-title><source>Cancers</source><volume>13</volume><elocation-id>34201346</elocation-id><pub-id pub-id-type="doi">10.3390/cancers13122872</pub-id><pub-id pub-id-type="pmid">34201346</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Motoi</surname><given-names>T</given-names></name><name><surname>Khanin</surname><given-names>R</given-names></name><name><surname>Olshen</surname><given-names>A</given-names></name><name><surname>Mertens</surname><given-names>F</given-names></name><name><surname>Bridge</surname><given-names>J</given-names></name><name><surname>Dal Cin</surname><given-names>P</given-names></name><name><surname>Antonescu</surname><given-names>CR</given-names></name><name><surname>Singer</surname><given-names>S</given-names></name><name><surname>Hameed</surname><given-names>M</given-names></name><name><surname>Bovee</surname><given-names>JVMG</given-names></name><name><surname>Hogendoorn</surname><given-names>PCW</given-names></name><name><surname>Socci</surname><given-names>N</given-names></name><name><surname>Ladanyi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Identification of a novel, recurrent HEY1-NCOA2 fusion in mesenchymal chondrosarcoma based on a genome-wide screen of exon-level expression data</article-title><source>Genes, Chromosomes &amp; Cancer</source><volume>51</volume><fpage>127</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1002/gcc.20937</pub-id><pub-id pub-id-type="pmid">22034177</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watson</surname><given-names>S</given-names></name><name><surname>LaVigne</surname><given-names>CA</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Surdez</surname><given-names>D</given-names></name><name><surname>Cyrta</surname><given-names>J</given-names></name><name><surname>Calderon</surname><given-names>D</given-names></name><name><surname>Cannon</surname><given-names>MV</given-names></name><name><surname>Kent</surname><given-names>MR</given-names></name><name><surname>Silvius</surname><given-names>KM</given-names></name><name><surname>Kucinski</surname><given-names>JP</given-names></name><name><surname>Harrison</surname><given-names>EN</given-names></name><name><surname>Murchison</surname><given-names>W</given-names></name><name><surname>Rakheja</surname><given-names>D</given-names></name><name><surname>Tirode</surname><given-names>F</given-names></name><name><surname>Delattre</surname><given-names>O</given-names></name><name><surname>Amatruda</surname><given-names>JF</given-names></name><name><surname>Kendall</surname><given-names>GC</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>VGLL2-NCOA2 leverages developmental programs for pediatric sarcomagenesis</article-title><source>Cell Reports</source><volume>42</volume><elocation-id>112013</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2023.112013</pub-id><pub-id pub-id-type="pmid">36656711</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whittle</surname><given-names>S</given-names></name><name><surname>Venkatramani</surname><given-names>R</given-names></name><name><surname>Schönstein</surname><given-names>A</given-names></name><name><surname>Pack</surname><given-names>SD</given-names></name><name><surname>Alaggio</surname><given-names>R</given-names></name><name><surname>Vokuhl</surname><given-names>C</given-names></name><name><surname>Rudzinski</surname><given-names>ER</given-names></name><name><surname>Wulf</surname><given-names>A-L</given-names></name><name><surname>Zin</surname><given-names>A</given-names></name><name><surname>Gruver</surname><given-names>JR</given-names></name><name><surname>Arnold</surname><given-names>MA</given-names></name><name><surname>Merks</surname><given-names>JHM</given-names></name><name><surname>Hettmer</surname><given-names>S</given-names></name><name><surname>Koscielniak</surname><given-names>E</given-names></name><name><surname>Barr</surname><given-names>FG</given-names></name><name><surname>Hawkins</surname><given-names>DS</given-names></name><name><surname>Bisogno</surname><given-names>G</given-names></name><name><surname>Sparber-Sauer</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Congenital spindle cell rhabdomyosarcoma: an international cooperative analysis</article-title><source>European Journal of Cancer</source><volume>168</volume><fpage>56</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2022.03.022</pub-id><pub-id pub-id-type="pmid">35452896</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamaguchi</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Multiple roles of vestigial-like family members in tumor development</article-title><source>Frontiers in Oncology</source><volume>10</volume><elocation-id>1266</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2020.01266</pub-id><pub-id pub-id-type="pmid">32793503</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamashita</surname><given-names>K</given-names></name><name><surname>Baba</surname><given-names>S</given-names></name><name><surname>Togashi</surname><given-names>Y</given-names></name><name><surname>Dobashi</surname><given-names>A</given-names></name><name><surname>Ae</surname><given-names>K</given-names></name><name><surname>Matsumoto</surname><given-names>S</given-names></name><name><surname>Tanaka</surname><given-names>M</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Takeuchi</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Clinicopathologic and genetic characterization of angiofibroma of soft tissue: a study of 12 cases including two cases with AHRR::NCOA3 gene fusion</article-title><source>Histopathology</source><volume>83</volume><fpage>57</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1111/his.14899</pub-id><pub-id pub-id-type="pmid">36860189</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yi</surname><given-names>P</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>O’Malley</surname><given-names>BW</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Steroid receptor-coregulator transcriptional complexes: new insights from CryoEM</article-title><source>Essays in Biochemistry</source><volume>65</volume><fpage>857</fpage><lpage>866</lpage><pub-id pub-id-type="doi">10.1042/EBC20210019</pub-id><pub-id pub-id-type="pmid">34061186</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>WKK</given-names></name><name><surname>Liang</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>N</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Chan</surname><given-names>MTV</given-names></name><name><surname>Ng</surname><given-names>SSM</given-names></name><name><surname>Sung</surname><given-names>JJY</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Disruption of NCOA2 by recurrent fusion with LACTB2 in colorectal cancer</article-title><source>Oncogene</source><volume>35</volume><fpage>187</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1038/onc.2015.72</pub-id><pub-id pub-id-type="pmid">25823027</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zanconato</surname><given-names>F</given-names></name><name><surname>Forcato</surname><given-names>M</given-names></name><name><surname>Battilana</surname><given-names>G</given-names></name><name><surname>Azzolin</surname><given-names>L</given-names></name><name><surname>Quaranta</surname><given-names>E</given-names></name><name><surname>Bodega</surname><given-names>B</given-names></name><name><surname>Rosato</surname><given-names>A</given-names></name><name><surname>Bicciato</surname><given-names>S</given-names></name><name><surname>Cordenonsi</surname><given-names>M</given-names></name><name><surname>Piccolo</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth</article-title><source>Nature Cell Biology</source><volume>17</volume><fpage>1218</fpage><lpage>1227</lpage><pub-id pub-id-type="doi">10.1038/ncb3216</pub-id><pub-id pub-id-type="pmid">26258633</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Shi</surname><given-names>Z</given-names></name><name><surname>Guo</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Han</surname><given-names>X</given-names></name><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Ji</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>VGLL4 functions as a new tumor suppressor in lung cancer by negatively regulating the YAP-TEAD transcriptional complex</article-title><source>Cell Research</source><volume>24</volume><fpage>331</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1038/cr.2014.10</pub-id><pub-id pub-id-type="pmid">24458094</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Tumaneng</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>C-Y</given-names></name><name><surname>Guan</surname><given-names>K-L</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP)</article-title><source>Genes &amp; Development</source><volume>24</volume><fpage>72</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1101/gad.1843810</pub-id><pub-id pub-id-type="pmid">20048001</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Pan</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The hippo signaling pathway in development and disease</article-title><source>Developmental Cell</source><volume>50</volume><fpage>264</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2019.06.003</pub-id><pub-id pub-id-type="pmid">31386861</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.98386.3.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Shi</surname><given-names>Xiaobing</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00wm07d60</institution-id><institution>Van Andel Institute</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Convincing</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Valuable</kwd></kwd-group></front-stub><body><p>This is a <bold>valuable</bold> study describing how rhabdomyosarcoma fusion-oncogenes, VGLL2-NCOA2 and TEAD1-NCOA2, function at the genomic, transcriptional, and proteomic levels in multiple systems. The experimental data is <bold>convincing</bold>, supporting a model in which these fusion-oncogenes leverage TEAD transcriptional signatures independent of YAP/TAZ. This work offers new mechanistic insights into oncogenic gene fusion events and reveals potential therapeutic strategies for the treatment of rhabdomyosarcomas.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.98386.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Guo, Hue et al., is focused on understanding the epigenetic activity and functional dependencies for two different fusions found in spindle cell rhabdomyosarcoma, VGLL2::NCOA2 and TEAD1::NCOA2. They use a variety of models and methods; specifically, ectopic expression of the fusions in human 293T cells to perform RNAseq (both fusions), CUT&amp;RUN (VGLL2::NCOA2) and BioID mass spec (both fusions). These data identify that the VGLL2::NCOA2 fusion has peaks that are enriched for TEAD motifs. Further, CREBBP/EP300 CUT&amp;RUN support an enrichment of binding sites and three TEAD targets in VGLL2::NCOA2 and TEAD1::NCOA2 expressing cells. They also functionally evaluate genetic and chemical dependencies (TEAD inhibition), and found this was only effective for the VGLL2::NCOA2 fusion, and not for TEAD1::NCOA2. Using complementary biochemical approaches, they suggest (with other supporting data) the fusions regulate TEAD transcriptional outputs via a YAP/TAZ independent mechanism. Further, they expand into a C2C12 myoblast model and show that TEAD1::NCOA2 is transforming in colony formation assays and in mouse allograft. These strategies for TEAD1-NCOA2 are consistent with previous published strategies using VGLL2::NCOA2. Importantly, they show that a CREBBP/EP300 (a binding partner found in their BioID mass spec) small molecule inhibitor suppresses tumor formation using this mouse allograft model, and that the tumors are less proliferative, and have a reduction in transcriptional of three TEAD target genes. They complement in vivo data with biochemical approaches, and suggest this interface with EP300 (for VGLL2::NCOA2) is through the NCOA2 fusion partner, as Co-IP in HEK293T with a mutant fusion that does not contain NCOA2 loses the association with endogenous EP300. The data is interesting and suggests new biology for these fusion-oncogenes. However, the choice of 293T may limit the broad applicability of the findings. Strikingly, in 293T there was more transcriptional overlap with the VGLL2-NCOA2 fusion with the YAP<sc>5SA</sc> mutant than with TEAD1-NCOA2. Further, there is an additional opportunity to directly compare transcriptional profiles in 293T to the human disease and in the mouse allograft system to directly compare and discuss VGLL2-NCOA2 and TEAD1-NCOA2 histological differences or how A485 treatment may change the histology. Overall, the breadth of methods used in this study, and comparison of the two fusion-oncogene's biology is of interest to the fusion-oncogene, pediatric sarcoma, and epigenetic therapeutic targeting fields.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.98386.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>In the manuscript entitled &quot;VGLL2 and TEAD1 fusion proteins drive YAP/TAZ-independent transcription and tumorigenesis by engaging p300&quot;, Gu et al. investigated two Hippo pathway-related gene fusion events (i.e., VGLL2-NCOA2, TEAD1-NCOA2) in spindle cell rhabdomyosarcoma (scRMS). They demonstrate that these fusion proteins activate Hippo downstream gene transcription independently of YAP/TAZ. Using BioID-based mass spectrometry analysis, the authors identify histone acetyltransferase CREBBP/EP300 as a specific binding protein for VGLL2-NCOA2 and TEAD1-NCOA2 fusion proteins. Pharmacologically targeting EP300 inhibits the fusion proteins-induced Hippo downstream gene transcription and tumorigenesis.</p><p>Overall, this work provides novel mechanistic insights into scRMS-associated gene fusions in tumorigenesis and reveals potential therapeutic targets for cancer treatment. The manuscript is well-written and easy to follow. Below are a few comments based on the revised study.</p><p>(1) While the study majorly focuses on Hippo downstream gene transcription, a significant portion of genes regulated by the VGLL2-NCOA2 and TEAD1-NCOA2 fusion proteins are non-Hippo downstream genes (Fig. 3). Further characterization of how both Hippo and non-Hippo downstream genes contribute to fusion proteins-induced oncogenesis would enhance our understanding of scRMS etiology.</p><p>(2) A potential limitation of this study is the reliance on overexpression approaches to investigate VGLL2-NCOA2 and TEAD1-NCOA2 fusion genes, which may not fully reflect pathological conditions in scRMS patients. Despite this, the significant study offers valuable mechanistic insights into fusion genes-induced scRMS and provides molecular foundation for developing targeted therapies.</p></body></sub-article><sub-article article-type="author-comment" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.98386.3.sa3</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Guo</surname><given-names>Susu</given-names></name><role specific-use="author">Author</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0220qvk04</institution-id><institution>Shanghai Jiao Tong University</institution></institution-wrap><addr-line><named-content content-type="city">Shanghai</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Hu</surname><given-names>Xiaodi</given-names></name><role specific-use="author">Author</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0464eyp60</institution-id><institution>University of Massachusetts Medical School</institution></institution-wrap><addr-line><named-content content-type="city">Worcester</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Cotton</surname><given-names>Jennifer L</given-names></name><role specific-use="author">Author</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0464eyp60</institution-id><institution>University of Massachusetts Chan Medical School</institution></institution-wrap><addr-line><named-content content-type="city">Worcester</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Ma</surname><given-names>Lifang</given-names></name><role specific-use="author">Author</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0220qvk04</institution-id><institution>Shanghai Jiao Tong University</institution></institution-wrap><addr-line><named-content content-type="city">Shanghai</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Qi</given-names></name><role specific-use="author">Author</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0464eyp60</institution-id><institution>University of Massachusetts Medical School</institution></institution-wrap><addr-line><named-content content-type="city">Worcester</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Cui</surname><given-names>Jiangtao</given-names></name><role specific-use="author">Author</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0220qvk04</institution-id><institution>Shanghai Jiao Tong University</institution></institution-wrap><addr-line><named-content content-type="city">Shanghai</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Yongjie</given-names></name><role specific-use="author">Author</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0220qvk04</institution-id><institution>Shanghai Jiao Tong University</institution></institution-wrap><addr-line><named-content content-type="city">Shanghai</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Thakare</surname><given-names>Ritesh P</given-names></name><role specific-use="author">Author</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0464eyp60</institution-id><institution>University of Massachusetts Medical School</institution></institution-wrap><addr-line><named-content content-type="city">Worcester</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Tao</surname><given-names>Zhipeng</given-names></name><role specific-use="author">Author</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Ip</surname><given-names>Tony</given-names></name><role specific-use="author">Author</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0464eyp60</institution-id><institution>University of Massachusetts Medical School</institution></institution-wrap><addr-line><named-content content-type="city">Worcester</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Xu</given-names></name><role specific-use="author">Author</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Jiayi</given-names></name><role specific-use="author">Author</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0220qvk04</institution-id><institution>Shanghai Jiao Tong University</institution></institution-wrap><addr-line><named-content content-type="city">Shanghai</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Mao</surname><given-names>Junhao</given-names></name><role specific-use="author">Author</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0464eyp60</institution-id><institution>University of Massachusetts Medical School</institution></institution-wrap><addr-line><named-content content-type="city">Worcester</named-content></addr-line><country>United States</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Public Review):</bold></p><p>(1) The rationale for performing genomics, transcriptional, and proteomics work in 293T cells is not discussed. Further, there are no functional readouts mentioned in the 293T cells with expression of the fusion-oncogenes. Did these cells have any phenotypes associated with fusion-oncogene expression (proliferation differences, morphological changes, colony formation capacity)? Further, how similar are the gene expression signatures from RNA-seq to rhabdomyosarcoma? This would help the reader interpret how similar these cell models are to human disease.</p></disp-quote><p>We appreciate the reviewer’s comments and understand the limitation of HEK293T cell culture. HEK293T cells were used as a surrogate system that enabled us to systemically examine and compare the transcriptional activation mechanisms between VGLL2-NCOA2/TEAD1-NCOA2 and YAP/TAZ. HEK293T cells have previously been used as a model system to study the signaling and transcriptional mechanisms of the Hippo/YAP pathway (1,2). Our data also showed that the ectopic expression of VGLL2-NCOA2 and TEAD1-NCOA2 in HEK293 cells can promote proliferation (Figure 1-figure supplement 1B), consistent with their potential oncogenic function.</p><disp-quote content-type="editor-comment"><p>(2) TEAD1::NCOA2 fusion-oncogene model was not credentialed past H&amp;E, and expression of Desmin. Is the transcriptional signature in C2C12 or 293T similar to a rhabdomyosarcoma gene signature?</p></disp-quote><p>We understand the reviewer’s concern. VGLL2-NCOA2 in vivo tumorigenesis model generated by C2C12 cell orthotopic transplantation has recently been reported, and it exhibits similar characteristics with zebrafish transgenic tumors as well as human scRMS samples that carry the VGLL2-NCOA2 fusion (3). Due to the similar transcriptional and oncogenic mechanisms employed by both VGLL2-NCOA2 and TEAD1-NCOA2 fusion proteins, we expect that the TEAD1-NCOA2 dependent C2C12 transplantation model will closely resemble that induced by VGLL2-NCOA2.</p><disp-quote content-type="editor-comment"><p>(3) For the fusion-oncogenes, did the HA, FLAG, or V5 tag impact fusion-oncogene activity? Was the tag on the 3' or 5' of the fusion? This was not discussed in the methods.</p></disp-quote><p>To address the reviewer’s concern, we carefully compared the transcriptional activity of the fusion proteins with the HA tag at the 5’ end or FLAG and V5 tag at the 3’ end. We found that neither the tag type nor its location significantly affects the ability of VGLL2-NCOA2 and TEAD1-NCOA2 to induce downstream gene transcription, measured by qPCR. The data is summarized in Figure 1-figure supplement 1 G-H.</p><disp-quote content-type="editor-comment"><p>(4) Generally, the lack of details in the figures, figure legends, and methods make the data difficult to interpret. A few examples are below:</p><p>a. Individual data points are not shown for figure bar plots (how many technical or biological replicates are present and how many times was the experiment repeated?).</p></disp-quote><p>As requested, we have added the individual data points to the bar plots. The Method section now includes information on the number of biological replicates and the times the experiments were repeated.</p><disp-quote content-type="editor-comment"><p>b. What exons were included in the fusion-oncogenes from VGLL2 and NCOA2 or TEAD1 and NCOA2?</p></disp-quote><p>We have now included the exon structure organization of VGLL2-NCOA2 or TEAD1-NCOA2 fusions in Figure 1-figure supplement 1A.</p><disp-quote content-type="editor-comment"><p>c. For how long were the colony formation experiments performed? Two weeks?</p></disp-quote><p>We have included more detailed information about the colony formation assay in the Methods section.</p><disp-quote content-type="editor-comment"><p>d. In Figure 2D, what concentration of CP1 was used and for how long?</p></disp-quote><p>The CP1 concentration and treatment duration information has now been included in the figure legend and Methods section.</p><disp-quote content-type="editor-comment"><p>e. How was A485 resuspended for cell culture and mouse experiments, what is the percentage of DMSO?</p></disp-quote><p>The Methods section now includes detailed information on how A485 is prepared for in vitro and in vivo experiments.</p><disp-quote content-type="editor-comment"><p>f. How many replicates were done for RNA-seq, CUT&amp;RUN, and ATACseq experiments?</p></disp-quote><p>RNA-seq was done with three biological replicates and CUT&amp;RUN and ATAC-seq were performed with two biological replicates. This information is now included in the Methods section for clarification.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public Review):</bold></p><p>In the manuscript entitled &quot;VGLL2 and TEAD1 fusion proteins drive YAP/TAZ-independent transcription and tumorigenesis by engaging p300&quot;, Gu et al. studied two Hippo pathway-related gene fusion events (i.e., VGLL2-NCOA2, TEAD1-NCOA2) in spindle cell rhabdomyosarcoma (scRMS) and showed that their fusion proteins can activate Hippo downstream gene transcription independent of YAP/TAZ. Using the BioID-based mass spectrometry analysis, the authors revealed histone acetyltransferase CREBBP/EP300 as specific binding proteins for VGLL2-NCOA2 and TEAD1-NCOA2 fusion proteins. Pharmacologically targeting EP300 inhibited the fusion proteins-induced Hippo downstream gene transcription and tumorigenic events.</p><p>Overall, this study provides mechanistic insights into the scRMS-associated gene fusions in tumorigenesis and reveals potential therapeutic targets for cancer treatment. The manuscript is well-written and easy to follow.</p><p>Here, several suggestions are made for the authors to improve their study.</p><p>Main points</p><p>(1) The authors majorly focused on the Hippo downstream gene transcription in this study, while a significant portion of genes regulated by the VGLL2-NCOA2 and TEAD1-NCOA2 fusion proteins are non-Hippo downstream genes (Figure 3). The authors should investigate whether the altered Hippo pathway transcription is essential for VGLL2-NCOA2 and TEAD1-NCOA2-induced cell transformation and tumorigenesis. Specifically, they should test if treatment with the TEAD inhibitor can reverse the cell transformation and tumorigenesis caused by VGLL2-NCOA2 but not TEAD1-NCOA2. In addition, it is important to examine whether YAP-5SA expression can rescue the inhibitory effects of A485 on VGLL2-NCOA2 and TEAD1-NCOA2-induced colony formation and tumor growth. This will help clarify whether Hippo downstream gene transcription is important for the oncogenic activities of these two fusion proteins.</p></disp-quote><p>We thank the reviewer for the comments. Although we have not tested the small molecular TEAD inhibitor on VGLL2-NCOA2 or TEAD1-NCOA2-induced cell transformation and tumorigenesis, we expect that TEAD inhibition will block VGLL2-NCOA2- but not TEAD1-NCOA2-induced oncogenic activity. It is because TEAD1-NCOA2 does not contain the auto-palmitoylation sites and the hydrophobic pocket in the C-terminal YAP-binding domain of TEAD1 that the TEAD small molecule inhibitor occupies (4). We also appreciate the reviewer’s suggestion of YAP5SA rescue experiments. However, due to its strong oncogenic activity, YAP5SA itself can induce robust downstream transcription and cell transformation with or without A485 treatment, as shown in Figure 5. Thus, it will be unlikely to address whether non-Hippo downstream genes induced by the fusions are important for cell transformation and tumorigenesis. Because of the distinct nature of transcriptional and chromatin landscapes controlled by VGLL2-NCOA2/TEAD-NCOA2 and YAP, we speculate that both Hippo and non-Hippo-related downstream genes contribute to the oncogenic activation and tumor phenotypes induced by the fusion proteins.</p><disp-quote content-type="editor-comment"><p>(2) Rationale for selecting CBP/p300 for functional studies needs to be provided. The BioID-MS experiment identified many interacting proteins for VGLL2-NCOA2 and TEAD1-NCOA2 fusion proteins (Table S4). The authors should explain the scoring system used to identify the high-interacting proteins for VGLL2-NCOA2 and TEAD1-NCOA2 fusion proteins. Was CEP/p300 the top candidates on the list? Providing this information will help justify the focus on CBP/p300 and validate their importance in this study.</p></disp-quote><p>We appreciate the reviewer’s point. CBP/P300 is among the top hits in our proteomics screens of both VGLL2-NCOA2 and TEAD1-NCOA2. Our focus on CBP/P300 is mainly due to the well-established interactions between CBP/P300 and the NCOA family transcriptional co-activators, in which the CBP/P300-NCOA complex plays a central role in mediating nuclear receptors-induced transcriptional activation (5). In addition, our data is consistent with another re-current Vgll2 fusion identified in scRMS, VGLL2-CITED2 (6) that has a C-term fusion partner from CITED2, which is a known CBP/P300 interacting protein (7).</p><disp-quote content-type="editor-comment"><p>(3) p300 was revealed as a key driver for the VGLL2-NCOA2 and TEAD1-NCOA2 fusion proteins-induced transcriptome alteration and tumorigenesis. To strengthen the point, the authors should identify the p300 binding region on VGLL2-NCOA2 and TEAD1-NCOA2 fusion proteins. Mutants with defects in p300 binding/recruitment should be generated and included as a control in the related q-PCR and tumorigenic studies. This work will help confirm the crucial role of p300 in mediating the oncogenic effects of these two fusion proteins.</p></disp-quote><p>We thank the reviewer for the suggestion. We have performed the co-immunoprecipitation assay using the deletion mutant form of VGLL2-NCOA2. We have performed additional co-immunoprecipitation experiments and demonstrated that the C-term NCOA2 part of the fusion is responsible for mediating the interaction between the fusion protein and CBP/P300. These results are now included in the new Figure 5A and are consistent with the reported structural analysis of CBP/P300-NCOA complex (8). In addition, our new data showed the inability of the VGLL2-NCOA2 ∆NCOA2 mutant to induce gene transcription (Figure 1-figure supplement 1D). Furthermore, our data using the small molecular CBP/P300 inhibitor clearly demonstrated that CBP/P300 is required to mediate cell transformation and tumorigenesis induced by the two fusion proteins in vitro and in vivo (Figure 5 and 6).</p><disp-quote content-type="editor-comment"><p>(4) Another major issue is the overexpression system extensively used in this study. It is important to determine whether the VGLL2-NCOA2 and TEAD1-NCOA2 fusion genes are also amplified in cancer. If not, the expression levels of the VGLL2-NCOA2 and TEAD1-NCOA2 fusion proteins should be adjusted to endogenous levels to assess their oncogenic effects on gene transcription and tumorigenesis. This approach would make the study more relevant to the pathological conditions observed in scRMS cancer patients.</p></disp-quote><p>We appreciate the reviewer’s input and acknowledge the limitation of the HEK293T and C2C12 cell-based models that rely on ectopic expression of VGLL2-NCOA2 and TEAD1-NCOA2 fusion proteins. It is currently unclear whether the VGLL2-NCOA2 and TEAD1-NCOA2 fusion genes are also amplified in sarcoma. As mentioned before, these surrogate cell culture systems allowed us to systemically compare the transcriptional regulation by the fusion proteins and YAP/TAZ and elucidate the molecular mechanism underlying the Hippo/YAP-independent oncogenic transformation induced by VGLL2-NCOA2 and TEAD1-NCOA2.</p><p>References:</p><p>(1) Genes Dev . 2007 Nov 1;21(21):2747-61. doi: 10.1101/gad.1602907. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control</p><p>(2) Genes Dev . 2010 Jan 1;24(1):72-85. doi: 10.1101/gad.1843810. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP)</p><p>(3) VGLL2-NCOA2 leverages developmental programs for pediatric sarcomagenesis. Watson S, LaVigne CA, Xu L, Surdez D, Cyrta J, Calderon D, Cannon MV, Kent MR, Cell Rep. 2023 Jan 31;42(1):112013.</p><p>(4) Lats1/2 Sustain Intestinal Stem Cells and Wnt Activation through TEAD-Dependent and Independent Transcription. Cell Stem Cell. 2020 May 7;26(5):675-692.e8.</p><p>(5) Yi, P., Yu, X., Wang, Z., and O’Malley, B.W. (2021). Steroid receptor-coregulator transcriptional complexes: new insights from CryoEM. Essays Biochem. 65, 857–866.</p><p>(6) A Molecular Study of Pediatric Spindle and Sclerosing Rhabdomyosarcoma: Identification of Novel and Recurrent VGLL2-related Fusions in Infantile Cases. Am J Surg Pathol . 2016 Feb;40(2):224-35. doi: 10.1097/</p><p>(7) CITED2 and the modulation of the hypoxic response in cancer. Fernandes MT, Calado SM, Mendes-Silva L, Bragança J.World J Clin Oncol. 2020 May 24;11(5):260-274.</p><p>(8) Yu, X., Yi, P., Hamilton, R.A., Shen, H., Chen, M., Foulds, C.E., Mancini, M.A., Ludtke, S.J., Wang, Z., and O’Malley, B.W. (2020). Structural insights of transcriptionally active, full-length Androgen receptor coactivator complexes. Mol. Cell 79, 812–823.e4.</p></body></sub-article></article>